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Synopsis 
The role of serum autoantibodies, soluble adhesion molecules, plasma and 
mucosal cytokines were studied following surgery for ulcerative colitis (UC). 
A high prevalence of ANCA was found in UC but not in Crohn’s disease. 
ANCA positive UC sera were found to  recognise a variety of antigens, namely 
lactoferrin, cathepsin G, enolase and elastase. 
Confocal microscopy revealed maximum immunofluorescence for P-ANCA to  
emanate from the intranuclear and not the extra-(peri) nuclear portion of the 
neutrophil, as currently believed. 
AECA, like ANCA, are also found in UC, suggesting immunological similarities 
with systemic vasculitis. Perhaps, UC represents a gut limited vasculitis. 
Persistance of ANCA, AECA, anti-EPI and antitropomyosin antibodies in the sera, 
several years following total colectomy, suggests that immunological 
mechanisms are not halted, by total colectomy. 
Soluble intercellular cell adhesion molecules, ICAM-1 and E-Selectin, but not 
VCAM-1, were found to  be useful markers of disease activity in UC. 
Plasma levels of cytokines do not reflect disease activity, however, there is 
similar quantitative expression of pro-inflammatory cytokines by isolated 
mucosal mononuclear cells in both active UC and pouchitis, but not in non- 
specific proctitis, which seems to suggest that pouchitis is not merely a 
complication of ileoanal pouch surgery but, that it represents reactivation of UC 
in ileal mucosa, which has undergone villous atrophy and colonic metaplasia. 
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1.1 Historical perspective 
Chronic ulcerative colitis (UC) is an inflammatory disease 
of the colon, the chief symptom being diarrhoea with blood 
and mucus. In the nineteenth century it gradually became 
more clear that chronic UC was a pathological entity 
distinct from other known ulcerating diseases observed in 
the colon and rectum (the most common of which were 
dysentery and tuberculosis). 
The first report of UC has been ascribed to Sir Samuel 
Wilks (Figure 1.1), a physician and pathologist who lived 
from 1824 to 1911. In the first part of 1859 he wrote in 
his L e c t u r e s  of Pathological Anatomy [Wilks, 1859], that 
the term colitis could not be synonymous with dysentery. He 
described occasional findings of inflammation of the colon 
in certain febrile and other disorders without evident 
cause, 'patches of the colon being red, inflamed, covered with mucus, adherent 
lymph and ulceration'. 
In September 1859, Wilks presented his classic description 
of a case with severe UC, 'the morbid appearances in the 
intestine of Miss Banks',[Wilks, 1859], comprising 
testimony to court based on examinations a few days after 
her death for suspected poisoning. He described 'the mucous 
membrane was ulcerated from end to end, the majority of ulcers being the size of a 
sixpenny piece, and together occupying more than half the internal su face. The ulcers 
were of an active and very recent character, most pronounced in the proximal part 
of the large intestine, with sloughing, and almost detached, with exudation of blood, 
3 
Figure 1.1. Sir Samuel Wilks. (By kind permission of the Gordon Museum, Guys 
Hospital, London). 
4 
mixed with secretions'. Wilks believed that the severe changes 
were of two to three weeks standing and were the cause of 
death. He discussed the possibility that the ulcerating 
disease could commence in the mucosa or in the glands 
beneath. He described having seen two previous cases, out 
of 3000 autopsies at Guys Hospital, resembling the present 
one, he then concluded that, although the acute 
inflammation might be set up by an irritant poison, 'poison as 
a primary cause was most unlikely to produce the observed effects'. 
There has been significant advance in the diagnosis and 
management of patients with UC employing improved 
diagnostic aids such as endoscopic biopsy, histology and 
histochemical methods however despite this, the cause of UC 
after over one hundred and thirty years from the original 
description still remains to be elucidated. 
Over the years a number of theories have been proposed. 
Popular during the early years was that the disease 
represented a chronic form of bacillary dysentery or that 
it represented an allergic response to a dietary antigen. 
Recent work has focused more on the hypothesis that the 
defect may lie in the immunological response within the 
epithelium. Immunological effector mechanisms are thought 
to account for most of the tissue damage that occurs within 
the mucosa. However, what triggers these effector 
mechanisms is unknown. Some theories and pathophysiological 
mechanisms are considered. 
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1.2 Aetiological Factors 
1.21 Genetic Factors 
It is most likely that there is a genetic component. The 
observed frequency of the disease in first degree relatives 
is reported to be about 13% [Gilat, 1986]. This tendency 
has been shown to extend to cousins, uncles, and 
grandparents, but with a reduced frequency. As spouses of 
index cases are rarely affected, this is suggestive of a 
genetic predisposition. However, unlike Crohn’s disease, 
monozygotic twin studies have not shown such strong 
concordence for UC. No strong HLA association has emerged 
either, except in Japan where UC is reported to be 
associated with HLA-B5 and DR2 [Asakara et al, 1982; 
Tsuchiya et al, 1977]. After combining all the reported 
studies of HLA-A and -B antigens, an association (albeit 
weak) of HLA-B27 and -Bw35 with UC has been shown [Biemond 
et al, 1986; Satsangi et al, 1994]. 
1.22 Environmental Factors 
It has been postulated that increased permeability during 
infancy could lead to sensitization to one or more luminal 
antigens which could render an individual susceptible to 
chronic disease later in life. Early weaning [Acheson et 
al, 1979] and gastroenteritis in infancy [Whorwell et al, 
1979] have been suggested as possible risk factors but more 
recent studies have found no such evidence [Gilat et al, 
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1985]. 
A number of studies have shown an association between the 
non-smoking status and UC (the converse being the case with 
Crohn's disease). The mechanism underlying this association 
is unknown. It has been suggested that there might be a 
genetic predisposition to inflammatory bowel disease (IBD) 
and that the smoking habit might determine whether UC or 
Crohn's disease develops [Somerville et al, 1984]. 
Another factor which has been investigated is the oral 
contraceptive pill and this could point to a vascular basis 
for the disease, but reports have been conflicting [Royal 
College of General Practitioners, 1974; Rhodes et al, 1984; 
Vessey et al, 1986]. 
Investigations into diet and stress factors have not 
demonstrated any convincing correlations. The role played 
by free fatty acids is currently being evaluated (Sagar et 
al, 1994) 
1.23 Role of infectious agents 
In active UC, the mucosa is infiltrated by acute 
(neutrophils, basophils, eosinophils) and chronic 
(lymphocytes, plasma cells and macrophages) inflammatory 
cells. 
A number of infectious agents have been implicated in UC, 
but none has satisfied Koch's postulates of i)isolation 
from all cases, ii) pure growth in culture and iii) passage 
of cultured organism to an appropriate animal model. 
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Bacteria 
Many studies have shown changes in the proportions of 
commensal organisms in the normal gut. However, diarrhoea, 
irrespective of the primary aetiology, may itself bring 
about these changes. None of the early studies, which 
implicated bacteria from the normal flora, have been 
substantiated. Similarly, it is unlikely that UC is a 
chronic form of bacillary dysentery [Gorbach, 1986]. 
It appears that the intestinal microflora has a secondary 
rather than a primary role in UC [Mahida, 1987]. Bacteria 
appear to potentiate inflammation following penetration due 
to increased permeability caused by the initial breach in 
the epithelial barrier. Their role can perhaps be 
illustrated, to some extent, in an animal model. 
Administration of a red seaweed extract, carageenan, to 
guinea pigs produces a form of colonic inflammation that, 
in some ways resembles human UC. This inflammation is 
prevented if the animals are kept germ free or are given 
oral metronidazole [Onderdonk et al, 1981]. However, 
metronidazole does not appear to have a role in the 
treatment of UC [Chapman et al, 1986] but it does however 
form the mainstay treatment of pouchitis. 
Viruses 
There is no convincing evidence to date of a specific viral 
aetiology. Measles virus has been implicated in Crohn's 
disease, recently, by Wakefield [Wakefield et al, 1992]. 
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1.3 Immunological factors 
Interest in the role of the immune response in UC arose 
because of a number of observations. These included the 
nature of the mucosal inflammation, the occasional 
association with autoimmune disorders and the observation 
that gammaglobulin concentrations increased during relapse. 
Many studies have been performed and it has been shown that 
heightened immune responses, as shown by humoral and cell 
mediated immunity, to a variety of gut associated antigens 
occur. 
1.31 Immune complexes and complement 
The idea that antigen-antibody complexes mediate the 
inflammation in UC is attractive as it could explain not 
only the colonic inflammation but also its association with 
extra-intestinal manifestations like arthritis, uveitis and 
erythema nodosum. Circulating immune complexes have been 
related to disease activity and extra-intestinal 
manifestations [Jewell et al, 1983]. It is presumed that 
immune complexes in the intestinal mucosa would activate 
complement which would lead to tissue damage. This has been 
supported by animal experiments. Deposition of immune 
complexes within the colonic mucosa of rabbits leads to an 
acute inflammation which is quite similar to human UC. 
Morever, if these animals are previously immunized to 
bacterial antigens, the injection of soluble immune 
complexes induces chronic colitis [Mee et al, 1979]. 
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1.32 Autoimmunity 
Autoimmunity was suggested by the demonstration of 
anticolon antibodies which were first described in patients 
with UC in 1959 [Broberger et al, 1959]. The antibodies are 
directed towards an antigenic determinant in the goblet 
cells of the colonic epithelium, and cross-react with 
lipopolysaccharide extracts of E.Coli. However, these 
antibodies are not specific for UC and can be detected in 
a number of other clinical conditions [Jewell et al, 1985]. 
Colonocyte specific cytotoxic antibody has also been 
described [Shorter et al, 1970; Das et al, 1984; Auer et 
al, 1988]. The relation between these two characterised 
antibodies is unclear and their importance in the 
pathogenesis of ulcerative colitis is uncertain. 
Recently, a possible target antigen for the anticolon 
antibody has been described by Das and colleagues to be an 
isoform of the muscle protein tropomyosin. Anti-tropomyosin 
antibody has been found to be present in the majority of 
patients with UC but not in Crohn's disease. Tropomyosin is 
expressed not only by the colon but also by many other 
organs, including the gall bladder and skin, which possibly 
provides an explanation for the biliary and cutaneous 
manifestations of UC [Das et al, 1990, Das et al 1992]. 
Several other autoantibodies have now been described in 
IBD. These include the anti-neutrophil cytoplasmic 
antibody (ANCA) and antiendothelial cell antibody (AECA). 
10 
1.33 ANCA 
A relatively new type of antibody which has received 
considerable interest recently is the anti-neutrophil 
cytoplasmic antibody (ANCA). ANCA can be detected by 
indirect immunofluorescence on alcohol fixed neutrophils. 
ANCA has been described in detail originally in patients 
with systemic vasculitides and is currently used to aid 
diagnosis and monitor disease process in this group of 
diseases [Davies et al, 1982; Van der Woude et al, 1985; 
Rasmussen et al, 1988; Falk et al, 1988; Gross et al, 
1990]. In these diseases the related antigens are enzymes 
in the granules of neutrophils [Falk et al, 1988; Ludemann 
et al, 1990; Goldschmeding et al, 1989; Pryzwansky et al, 
1978; Niles et al, 1989; Lee et al, 1990]. In essence two 
types of ANCA have been shown by indirect 
immunofluorescence: 
i) C-ANCA: antibody directed against neutrophil cytoplasm 
in a diffuse manner 
ii) P-ANCA: antibody directed against the perinuclear 
cytoplasm of the neutrophil 
Several studies have reported the existence of P-ANCA in 
the majority of patients (50-83 % )  with ulcerative colitis 
and 10-30% of patients with Crohn's disease [Saxon et al, 
1990; Rump et al, 1990; Siebold et al, 1992; Cambridge et 
al, 1992]. 
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1.34 AECA 
Anti-endothelial cell antibodies (AECA), were originally 
implicated as a pathogenic factor in the vascular injury 
induced in patients with systemic lupus erythematosus 
[Cines et al, 1984]. Since then they have been reported to 
occur in Kawasaki syndrome [Leung et al, 1986; Leung et al, 
1987], haemolytic uraemic syndrome [Leung et al, 1988], and 
rheumatoid vasculitis [Heurkens et al, 1989; Quadros et al, 
1990]. Recently, several studies have reported that sera 
from 30-60 % of patients with polyarteritis and Wegener's 
granulomatosis contain antibodies to endothelial cells 
[Ferraro et al, 1990; Frampton et al, 1990; Savage et al, 
1991]. 
The role of AECA in the vasculitic disorders and mechanisms 
by which vascular injury may be brought about is well 
documented [Cines et al, 1984; Leung et al, 1986; Leung et 
al, 1987; Leung et al, 1988]. Although vasculitis has been 
documented in inflammatory bowel disease very little is 
known of the mechanisms involved [Murch et al, 1992; 
Wakefield et al, 1991]. 
AECA have been recently described in IBD [Romas et al, 
1992; Stevens et al, 1993] but, as yet, their role has not 
been clearly defined in this group of diseases. 
The problem of determining whether the humoral and cell- 
mediated immune responses to cell-associated antigens occur 
as a primary event or are secondary to the inflammation is 
unresolved. 
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Immunoregulation 
Tissue damage induced by immunological effector mechanisms 
could imply disordered immunoregulation. This is the 
process by which immune responses are controlled and 
include lymphocytes and macrophages. Communication within 
the microenvironment between the various immune cells is 
thought to occur via the production of monokines (peptides 
produced by mononuclear cells) or lymphokines (produced by 
lymphocytes) . 
1.4 Adhesion molecules 
The survival of any complex multicellular organism depends 
on the ordered and controlled interaction of its various 
specialised cells with one another and with the surrounding 
extracellular matrix (ECM). In the case of leucocytes, 
migration into and within the tissue requires co-ordinated 
expression and function of cell adhesion molecules (CAM) 
which mediate adhesion to other cells and to components of 
ECM. The application of monoclonal antibody and molecular 
biological techniques has considerably increased our 
understanding of the mechanisms of leucocyte adhesion. 
The classification and detailed description of leucocyte 
adhesion molecules and their ligands has been the subject 
of recent reviews [Albelda et al, 1990; Springer, 1990; 
Keelan et al, 19921. 
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1.41 Role of leucocyte adhesion molecules in inflammation 
Direct inspection of the microvasculature shows that 
circulating leucocytes normally ‘roll’ along the surface of 
the vessel wall [Atherton et al, 1972]. In inflamed tissues 
the rolling leucocyte becomes tethered to endothelium and 
subsequently, transmigrates through the vessel wall into 
the tissues. To a large extent, these different events in 
leucocyte emigration depend upon i) expression and 
activation of appropriate adhesion molecules on endothelial 
cells and ii) leucocytes in response to the mediators of 
the various forms and stages of inflammation. 
Endothelial cells and other resident cells 
The critical mechanism localising inflammatory lesions is 
probably the activation of adhesion molecule expression on 
endothelial cells and resident cells within the tissues. 
Endothelial cells can undergo different phases of 
activation, each associated with the appearance of 
different adhesion molecules for leucocytes. 
In very early inflammatory lesions translocation of pre- 
formed GMP-140 to the endothelial cell surface allows 
binding of neutrophils, monocytes and probably eosinophils. 
This is followed, after 4 - 6 hours, by sub-acute phase of 
endothelial activation, governed by the induction of a 
number of genes in response to interleukin 1 and/or tumour 
necrosis factor and involving the de novo synthesis and 
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expression of ICAM-1, ELAM-1 and VCAM-1 [Pober et al, 
1990]. The expression of these three cytokine inducible 
molecules is differentially regulated by cytokines, 
potentially resulting in alterations in their relative 
densities in different forms of immune mediated 
inflammation and thereby, predisposing to the migration of 
lymphocytes and monocytes [Thornhill et al, 1991]. The 
nature of the endothelial adhesion molecules responsible 
for lymphocyte traffic in established chronic inflammation 
is not yet clear. New techniques have now been developed 
to measure not only tissue-bound adhesion molecules, by 
specific stains using monoclonal antibodies, but soluble 
forms can also now be measured to assess chronic 
inflammation. 
Clinical inflammation 
In the more complex forms of inflammation presented by 
clinical pathological material, expression of adhesion 
molecules can give insight into pathophysiological 
mechanisms and may even have diagnostic significance. 
Cytokines also regulate the expression of adhesion 
molecules on other resident cells such as epithelial cells, 
fibroblasts and synovial cells, the optimal stimuli for 
expression of individual molecules varying with cell type. 
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1.5 Cytokines 
The immunology of UC to unravel the intricacies of the 
inflammatory response has recently received great interest 
in the hope of finding abnormal regulatory events 
responsible, if not for triggering, at least for the 
perpetuation of the local tissue damage. If this less than 
ideal goal could be achieved a more rational and effective 
approach to the therapy of IBD could result [Fiocchi, 
1993]. 
In the strict sense, cytokines are products secreted by 
activated immune cells. These molecules share certain 
typical features, such as a multiplicity of cellular 
sources, activity on essentially all cell types, and 
functions integrated in a complex, redundant, but 
coordinated system called the 'cytokine network' [Balkwill 
et al, 1989]. Their presence in tissues and biological 
fluids is a physiological phenomenon, a premise that 
supports the widely held notion that alterations of their 
levels reflect abnormalities associated with a variety of 
pathological conditions. This notion explains in part, the 
tremendous interest all over the world in this 'cytokine 
explosion' [Durum et al, 1990]. Another reason for this 
interest is that fundamental cell-to-cell regulatory events 
are mediated primarily by cytokines [Sporn et al, 1992]. 
Therefore, the study of these soluble mediators holds the 
potential for answering basic biological questions while 
providing clinically valuable markers. Unfortunately, 
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nothing in science is as good as it seems to be, and the 
study of cytokines is no exception. When applied to IBD, 
data gathered from evaluation of cytokines have provided 
insight into possible pathogenic mechanisms [Fiocchi et al, 
1984], novel methods of monitoring disease activity 
[Mueller et al, 1990], or even the possibility of 
differentiating Crohn's disease from UC [Gross et al, 
1992]. On the other side, there still are many unsolved 
questions. The seemingly endless number of these molecules 
continues to lure the investigators into looking at still 
another, just discovered cytokine with a new irresistible 
function, distracting and detracting from the study of 
'older' mediators, whose spectrum of biological activity 
has barely been scratched in the labarotory. This results 
in a practical dilemma: which cytokines are really 
important in IBD? The 'old' or the 'new' ones? The low 
level, mostly T cell-derived products with a predominant 
immunoregulatory function, such as IL-2, IL-4, IL-10, 
interferon gamma, etc or the abundant, mainly 
monocyte/macrophage derived molecules with a potent pro- 
inflammatory effect such as interleukin-1ß (IL-l) , 
interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour 
necrosis factor Q (TNFa)? 
This artificial but practical dicotomy poses the question 
of choosing between the study of primary regulatory events 
that may reveal basic pathogenic events and the 
investigation of secondary mechanisms of tissue injury that 
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may pave the way to a truly efficacious therapy for Crohn's 
disease and UC. This choice seems unscientific but no one 
can study all cytokines that may be relevant to these 
conditions, and each investigator must be content in 
focusing on selected molecules at the best of his or her 
ability. To do so it is vital that one studies each 
molecule with a systematic and thorough approach. Levels of 
cytokines must be established in the circulation as well as 
in surgical and biopsy specimens, keeping in mind, however 
that simple information on serum and mucosal concentrations 
has limited value without knowing the exact secretory cell, 
receptor expression, binding characteristics, target cells, 
and effects [Matsura et al, 1992]. However, without 'going 
back to basics' further work will be plagued with 
discrepancies. In Figure 1.2 is shown a possible role of 
cytokines and inflammatory cells involved in the host 
response to foreign antigens. 
The cytokines studied in this thesis are the pro- 
inflammatory cytokines:- IL-1ß, IL-6, IL-8 and TNFa. 
1.51 Interleukin-1 
Original terms 
Endogenous pyrogen, lymphocyte activating factor (LAF). 
Biochemistry 
Molecular weight 17 000. IL-1 exists in two forms, a! and ß, 
coded by two separate genes. IL-la! is predominantly 
membrane associated, whilst IL-1ß is secreted. 
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Source. 
Although IL-1 is produced by many cells, cells of the 
mononuclear phagocyte system (monocytes/macrophages) are 
probably the major source. 
Table 1.1 Biological actions of IL-1 
As can be seen in Table 1.1, IL-1 has an effect on a large 
number of cells to produce a wide range of effects 
[Malkovsky et al 1988] and this serves to be a good example 
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to show the pleiotropic actions exhibited by cytokines. It 
induces T-cell activation, induces production of a number 
of cytokines and affects functions of B-cells, monocytes 
and neutrophils. Endothelial cells are induced to express 
adhesion molecules for neutrophils and lymhocytes upon 
stimulation with IL-1. This would allow the latter cells to 
interact with the endothelial cells and migrate to the site 
of inflammation. 
Relevance to gastroenterology 
Increased IL-1 production has been shown in both animal 
models of colitis [Rachmilewitz et al 1988] and in active 
human inflammatory bowel disease. Researchers [Satsangi et 
al, 1987] using a bioassay showed spontaneous production of 
IL-1 by isolated peripheral blood mononuclear cells from 
some patients with active Crohn's disease. 
In vitro synthesis of IL-1ß by isolated intestinal 
mononuclear cells has also been studied [Mahida et al, 
1989a]. There was enhanced production of the cytokine by 
mononuclear cells from mucosa with active inflammatory 
bowel disease compared with cells from control mucosa. 
Depletion of the mononuclear cells of macrophages reduced 
the amount of IL1-ß produced suggesting that these cells 
are the predominant producers of these cytokines in the 
intestinal mucosa. These results have recently been 
confirmed using a bioassay [Simon et al, 1989]. High levels 
of IL-1 have also been shown to be present in mucosal 
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biopsy specimens obtained from patients with active 
inflammatory bowel disease. %-aminosalicylic acid, at 
concentrations much lower than those found in the colonic 
lumen of patients taking this drug, inhibited synthesis of 
IL-1 in organ cultures of inflamed biopsies [Lamming et al, 
1989]. Dexamethasone but not sulphapyridine also inhibited 
synthesis of this cytokine. 
It is likely that interleukin-1 plays a major role in the 
pathogenesis of inflammatory bowel disease as it is a 
primary Stimulator of diarrhoea, the major symptom of 
intestinal inflammation [Sartor, 1994]. 
1.52 Interleukin-6 (IL6) 
Original terms. B-cell stimulating factor 2, B-cell 
differentiation factor. 
Biochemistry. Molecular weight 25  000. 
Source. Monocytes, T-cells, fibroblasts, endothelial cells. 
Biological actions. IL-6 has been shown to stimulate 
immunoglobulin synthesis by B-cells. Its actions on T-cells 
include acting as a Co-Stimulator in proliferation and also 
as cytolytic T-cell differentiation factor. Like IL-1 it 
induces synthesis of acute-phase proteins by hepatocytes 
[O'Garra, 1989b]. 
Relevance t o  gastroenterology 
IL-6 is known to regulate immune responses, haematopoiesis 
and perhaps more importantly in IBD, the acute phase 
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response [Thomson, 1991]. The latter is a systemic response 
to inflammation and tissue injury which is characterised by 
leucocytosis, fever, increased vascular permeability, 
alterations in plasma metal and steroid concentrations 
together with increased levels of acute phase proteins. 
This symptom complex is not uncommon in IBD. 
High circulating levels of IL-6 have been shown in acute 
pancreatitis [Leser et al, 1989; Heath et al, 1993] and in 
active inflammatory bowel disease [Mahida et al, 1990, 
Hyams et al, 1993]. where they correlated with severity of 
disease. 
1.53 Interleukin 8 (IL8) 
Synonyms. Monocyte derived neutrophil chemotactic factor 
(MNCF) , neutrophil activating peptide-1 (NAP-1) , neutrophil 
activating factor (NAF) . 
Biochemistry. Molecular weight 10 000. 
Source. Cells of the mononuclear/macrophage system are 
probably the main source. IL-8 can also be produced by 
fibroblasts, epithelial cells, endothelial cells and 
hepatocytes. 
Biological actions. 
IL-8 is a potent chemotactic factor for neutrophils and 
could well represent the first signalling mechanism from 
activated macrophages to attract neutrophils to the site of 
an early inflammatory lesion. It has other effects on 
activated neutrophils, which include release of stored 
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enzymes, production of reactive oxygen metabolites and 
expression of cell-surface adhesion molecules. It is also 
chemotactic for T-cells [Baggiolini et al, 1989]. 
Neutrophil accumulation in the inflamed intestinal mucosa 
is a prominent feature in ulcerative colitis. Activated 
neutrophils may contribute to tissue damage at sites of 
inflammation. The factor(s) responsible for the mucosal 
recruitment of neutrophils in ulcerative colitis is not 
certain. IL-8 was originally isolated from endotoxin 
treated monocytes but can also be produced by a variety of 
other cells upon stimulation with a number of cytokines 
including IL-1 and TNFa [Striter et al, 1988; Striter et 
al, 1989, Watson et al, 1988]. 
Relevance to gastroenterology 
There are, as yet, no conclusive data but it is highly 
likely that IL-8 could be pivotal in stimulating early 
neutrophil involvement in inflammatory diseases such as 
ulcerative colitis. Adhesion molecules induced on 
endothelial cells by IL-1 and TNF would allow neutrophils 
to interact with these cells. The neutrophils could then 
migrate under the influence of IL-8 into the mucosa. 
Subsequent production of leukotrienes would then lead to 
further Chemotaxis of neutrophils into the mucosa. IL-8 
could thus be a therapeutic target. Inhibitors of 
synthesis or release of antagonists to its receptor could 
have a role in the treatment of inflammatory bowel disease. 
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1.54 Tumour Necrosis Factor a 
TI 
Synonym. Cachectin 
Biochemistry. Molecular weight Fa) 17 000. 
Source. Principally cells of the mononuclear phagocyte 
system. 
Biological actions. TNFa has a wide range of effects, which 
induce killing, stimulation of growth and induction of 
differentiation of cells [Tracey et al 1989]. Acute 
systemic release of this cytokine induces shock. It has 
also been implicated in cachexia of malignancy and chronic 
infection. A wide range of biological properties have also 
been implicated in inflammation. It shares many of these 
with IL1, synthesis of which it can induce in cells of the 
mononuclear phagocyte system. Properties it shares with IL- 
1 include induction of adhesion molecules for neutrophils 
and lymphocytes and induction of pro-coagulant activity on 
endothelial cells, proliferation of fibroblasts, activation 
of neutrophils, induction of fever, elevation of 
acute-phase proteins and decreased albumin synthesis by 
hepatocytes. 
Relevance to gastroenterology 
The role of TNFa in gastrointestinal diseases is currently 
unknown. TNFa could be implicated in cachexia of 
gastrointestinal malignancy and active inflammatory bowel 
disease, especially Crohn's disease. Elevated plasma 
levels have been reported in patients with Crohn's disease 
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[Sartour, 1994]. Preliminary studies have shown no 
significant difference in the amount of TNFa produced by 
mononuclear cells isolated from histologically normal 
colonic mucosa and those cells isolated from mucosa with 
active inflammatory bowel disease. This is in contrast to 
the enhanced production of IL-1 by mononuclear cells from 
inflamed mucosa [Mahida et al 1989c]. Expression of 
TNF-specific messenger RNA has been demonstrated in mucosal 
mononuclear cells in cytomegalovirus enteritis [Lamerson et 
al 1989]. 
Intravenous infusion of high doses of TNFa have been shown 
to produce shock, diarrhoea, necrosis of epithelial and 
endothelial cells, degranulation of Paneth cells, luminal 
extravasation of neutrophils and red blood cells in the 
colon and small intestine. Infusion of TNFa over a period 
of 10 days has been shown to cause acute and chronic 
inflammation of the intestinal lamina propria and submucosa 
with focal mucosal ulceration, weight loss, bile duct 
proliferation, periportal inflammation, anaemia and 
leucocytosis [Sartour, 1994]. These are not unlike the 
symptoms of severe UC. 
Pro-inflammatory cytokines also induce epithelial 
expression of other cytokines such as IL-2, IL-4, IL-10, 
TGFB, Class I and II major histocompatibility complex 
antigens and manganese dependant superoxide dismutase. 
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Early reports that raise the possibility that tissue 
cytokine concentrations can assist in the differential 
diagnosis of intestinal inflammation such as :- 
i)IL-2 and interferon y are increased in mucosal biopsy 
results from patients with Crohn's disease but not in UC 
[Mullin et al, 1992, Breese et al, 1993] and 
ii)IL-10 is increased in UC but not in Crohn's disease need 
further verification. 
A distinct disorder of intestinal inflammation which may 
occur after restorative proctocolectomy is broadly known as 
pouchitis. This occurs in the neorectum created from the 
terminal ileum after an ileoanal pull-through procedure in 
the management of ulcerative colitis. Although the actual 
relation of this disorder to IBD remains uncertain, it may 
offer in vivo experimental models that could provide 
insight into the pathophysiologic processes contributing to 
ulcerative colitis. Pouchitis is found predominantly in 
patients with pre-existing ulcerative colitis and only 
infrequently in patients undergoing the same operation for 
familial polyposis coli [Lohmuller et al, 1990] and the 
simultaneous study of patients with IBD and pouchitis forms 
the basis of this study. 
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1.60 AIMS 
1.To assess the prevalence and titres of ANCA following 
surgery for UC looking especially at patients who had 
undergone restorative proctocolectomy. 
2.Determination of the antigen specificity of ANCA. 
3.To determine the target site of ANCA ie the exact 
morphological site of antigen-antibody binding which gives 
rise to the P-ANCA and C-ANCA immunofluorescence patterns 
in IBD using confocal scanning laser microscopy. 
4.To assess the prevalence of AECA following surgery for UC 
looking especially at patients who had undergone 
restorative proctocolectomy. 
5.To assess the prevalence of anti-EPI antibodies in UC.  To 
also assess whether the autoantibodies ANCA, AECA and Anti- 
EPI correlated with disease activity or treatment and 
whether they were cross-reactive with each other. 
6.The aims of this study were to determine levels of the 
soluble cell adhesion molecules in patients with chronic 
IBD in relation to prevalence, treatment and disease 
activity. 
7.The aims of this study were to investigate the role of 
the pro-inflammatory cytokines in IBD. Plasma levels of 
these cytokines were determined at the same time as trying 
to establish the local production in the colon by means of 
colonic and ileal tissue biopsies. 
8.The aims of this particular study were to assess whether 
there was increased cytokine production in pouchitis and if 
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so, are the levels of these cytokines comparable to UC. 
This hypothesis would put further weight on the belief that 
pouchitis did indeed represent reactivation of UC. 
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Chapter 2 
The influence of total colectomy on serum anti-neutrophil cyto- 
plasmic antibodies in inflammatory bowel disease 
2.1 
2.2 
2.3 
2.4 
2.5 
Introduction 
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Results 
Discussion 
Summary 
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2.1 Introduction 
The causes and pathogenesis of inflammatory bowel disease 
are still unclear. A relatively new type of antibody which 
has received considerable interest recently is the 
anti-neutrophil cytoplasmic antibody (ANCA) . ANCA can be 
detected by indirect immunofluorescence on alcohol fixed 
neutrophils (Figures 2.1 & 2.2). ANCA has been described in 
detail originally in patients with systemic vasculitides 
and is currently used to aid diagnosis and monitor disease 
process in this group of diseases [Davies et al, 1982; Van 
der Woude et al, 1985; Rasmussen et al, 1988; Falk et al, 
1988; Gross et al, 1990]. In these diseases the related 
antigens are enzymes in the granules of neutrophils [Falk 
et al, 1988; Ludemann et al, 1990; Goldschmeding et al, 
1989; Pryzwansky et al, 1978; Niles et al, 1989; Lee et al, 
1990]. In essence, two types of ANCA have been shown by 
indirect immunofluorescence: 
i) P-ANCA: antibody directed against the perinuclear 
cytoplasm of the neutrophil (Figure 2.1) 
ii) C-ANCA: antibody directed against neutrophil cytoplasm 
in a diffuse manner (Figure 2.2) 
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Granulocyte specific anti-nuclear antibodies (GS-ANAS) were 
reported even earlier than ANCA in 1966 [Farber et al, 
1966], primarily in patients with rheumatoid arthritis, 
although there are now reports of their being found in 
diseases such as SLE, drug induced lupus, chronic active 
hepatitis and myasthenia gravis [Wiik, 1980]. GS-ANAS were 
reported in a preliminary study in the sera of patients 
with IBD in 1983, (25% in UC and 3% in Crohn's disease) 
[Nielson et al, 1983]. It is likely that what was 
interpreted as nuclear staining was, in fact, the diffuse 
cytoplasmic staining with perinuclear highlighting that has 
since been reported in the sera of IBD patients [Saxon et 
al, 1990]. 
Several studies have reported the existence of P-ANCA in 
the majority of patients (50-83 % )  with ulcerative colitis 
and 10-30% of patients with Crohn's disease [Saxon et al, 
1990; Rump et al, 1990; Siebold et al, 1992; Cambridge et 
al, 1992]. 
Our study focuses on the prevalence of ANCA following 
surgery and especially total colectomy in inflammatory 
bowel disease. 
2.2 Patients and methods 
Sera taken from patients and healthy controls were coded 
and stored at -80 degrees Celsius. The diagnosis of 
inflammatory bowel disease in the study group had been made 
by prior clinical, radiological, endoscopic and 
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histopathological methods. 
Ulcerative Colitis 
101 patients with ulcerative colitis, median age 40, range 
16-72 years, and 55 were males. These patients were graded 
into 3 groups (mild to severe) according to criteria, as 
previously described [Kodner et al, 1990], in a modified 
form including endoscopic findings (Table 1) , and in two 
further groups who had surgical intervention (Table 2). Two 
patients who had undergone restorative proctocolectomy had 
also undergone prior liver transplantation for sclerosing 
cholangitis. 
Table 3 shows 12 patients who had blood samples taken 
before, 6-8 weeks and 6 months after total colectomy for 
severe ulcerative colitis. 5 patients who had undergone 
restorative proctocolectomy had clinical evidence of 
pouchitis when they were tested for ANCA. There were also 
5 patients with indeterminate colitis who had had colectomy 
but there was doubt on histopathological grounds as to 
whether the diagnosis was Crohn's or ulcerative colitis. 
Crohn's disease 
There were 40 patients with Crohn's disease, median age 30, 
range 18-65, and 22 were males. Disease activity was 
assessed using the Crohn's disease activity index [Harvey 
et al, 1980]. The median disease duration was 6 years 
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(range 1-15 years). 8 patients had disease confined to the 
colon/rectum, 12 confined to small bowel alone and 20 
affecting both large and small bowel. 4 patients included 
in the above groups had an ileostomy after undergoing 
proctocolectomy for Crohn's colitis. 
Controls 
There were 2 control groups of patients:- 24 healthy 
volunteers whose median age was 34.1 years, range 21-41 
years (Table 4) and 24 non-inflammatory bowel disease whose 
median age was 37.1 years and range 21- 58 years (Table 5). 
Preparation of Human Neutrophils 
Blood was taken from healthy group O+ve individuals, in 
endotoxin-free tubes, to prevent activation of neutrophils. 
The neutrophils were separated using Percoll gradients. 
The cytocentrifuge preparation of neutrophils was then 
applied to slides and fixed with ethanol. Commercially 
produced precoated neutrophil slides were also used to 
standardise indirect immunofluorescence readings (Inova, 
Minneapolis USA). The slides were stored at 4° C and brought 
to room temperature before use. 
Indirect Immunofluorescence 
Test sera diluted 1 in 20 with phosphate buffered saline 
(PBS) were incubated on the neutrophil coated slides for 30 
3 6  
minutes. After washing in a water bath for 30 minutes, FITC 
anti-human IgG (The Binding Site, Birmingham) was then 
placed on the slides ( 1 in 80 dilution) and incubated for 
30 minutes. After washing and fixing with DABCO (fixing 
reagent) the slides were read on the Leitz Orthoplan 
immunofluorescence microscope by two independent observers 
at 50X magnification. 
Anti-nuclear Antibodies 
Five sera, which suggested the presence of anti-nuclear 
antibody on indirect immunofluorescence, were tested using 
pre-coated slides with Hep-2 cells (The Binding Site, 
Birmingham) . 
Statistics 
Results were not normally distributed and are expressed as 
medians with ranges. Comparisons of the prevalence and 
titres of ANCA, in different subjects, have been made using 
the Chi square test and the Mann-Whitney U test. 
2.3 Results 
The predominant pattern was P-ANCA on indirect 
immunofluorescence. Inter-observer variation in the 
interpretation of indirect immunofluorescence readings was 
< 2 %. Overall 71/101 (70.3%) of the sera from patients 
with UC had P-ANCA and 5/101 (4.9 %) had C-ANCA (Table 1 & 
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2). 63.2 % of sera of patients having had subtotal 
colectomy who still had a rectum had P-ANCA. What seems 
very interesting is that 29/39 (74.4%) of the sera of 
patients, who had undergone restorative proctocolectomy, 
had P-ANCA. These patients had had removal of the primary 
target of the inflammatory process (the colon, rectum and 
anal mucosa) and yet still have high titres of ANCA. I have 
also noted that the titres of ANCA do not fall with time in 
the patients who have total colectomy as long as 4 years 
earlier. 
Table 2.1. Characteristics of ulcerative colitis patients 
by disease severity and ANCA distribution 
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Table 2.2 Characteristics of patients with ulcerative 
colitis who had undergone surgery and ANCA distribution. 
The median serum ANCA titre of 12 patients, who underwent 
total colectomy for ulcerative colitis, all of whom were 
known to have P-ANCA prior to surgery, doubled 6-8 weeks 
after surgery, and after 6 months the titre reverted to the 
preoperative titre (Table 3). Five patients with clinical 
pouchitis all had P-ANCA. 2 patients with ulcerative 
colitis, who had undergone liver transplantation for 
primary sclerosing cholangitis, prior to total colectomy, 
also had P-ANCA detectable in their sera. 
Table 2.3. Serial median ANCA titres over time in patients 
with ulcerative colitis following surgery. 
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In patients with Crohn's disease 10/40 (25%) were found to 
have P-ANCA and 1/40 (2.5%) C-ANCA. I found that from the 
10 out of the 40 patients with P-ANCA, 5 patients had 
undergone subtotal/total colectomy and 4 had evidence of 
Crohn's colitis. Only one patient with small bowel Crohn's 
has no evidence of the disease affecting the colon, as yet. 
Table 2.4.Characteristics of Crohn's disease, indeterminate 
colitis and control groups. 
ANCA was not demonstrated in any of the 24 healthy, or 24 
non-IBD sera, which were used as controls. 
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Table 2.5. Distribution of non-inflammatory bowel disease 
disorders. 
In our study group of patients, the effect of steroid and/ 
or salazopyrine therapy, did not seem in any way to affect 
the prevalence or titre of ANCA. There were no positive 
anti-nuclear antibodies detected on the five suspected sera 
using Hep2 cells. 
2.4 Discussion 
ANCA were originally described in the sera of patients with 
systemic vasculitis [Davies et al, 1982]. In this study it 
was shown that patients with idiopathic segmental 
necrotizing glomerulonephritis had detectable ANCA, which 
disappeared after treatment. Van der Woude then showed that 
ANCA were associated with active Wegener’s granulomatosis 
and, since then, many reports of its existence in various 
vasculitic conditions have been made [Van der Woude et al, 
1985; Rasmussen et al, 1988; Falk et al, 1988; Lee et al, 
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1990 ]. 
In 1990 ANCA were described in the sera of patients with 
IBD [Saxon et al, 1990; Rump et al, 1990] and these 
findings have been confirmed by others [Siebold et al, 
1992; Cambridge et al, 1992], including this study. In 
addition, this study has shown that the prevalence of ANCA 
is unaffected by surgery, especially total colectomy. ANCA 
detection in patients with systemic vasculitis has been 
found to aid in the clinical diagnosis and monitoring of 
disease activity following treatment [Van der Woude et al, 
1985; Lee et al, 1990]. However, the clinical value of ANCA 
in inflammatory bowel disease still needs further 
evaluation, since this study has found no correlation 
between the prevalence and titres of ANCA and medical 
treatment. 
In the 12 patients who had ANCA levels measured before and 
after total colectomy, it does not seem unusual that the 
ANCA titres temporarily doubled after 6-8 weeks, as this 
can be explained by the fact that these patients had prior 
severe colitis and the trauma induced by surgery may cause 
specific and non-specific increases in circulating 
immunoglobulins. However, what seems unusual, is the 
prevalence and high titres of ANCA for as long as 4 years 
after restorative proctocolectomy, in this series in 
asymptomatic patients. I believe that immunological 
mechanisms that resulted in UC are not halted by total 
colectomy. A possible reason for the persistence of ANCA 
4 2  
could be that chronic pouchitis may continually fuel the 
immunological process keeping levels of ANCA at detectable 
levels. ANCA have also been demonstrated in rheumatoid 
arthritis [Savige et al, 1991], and in a small percentage 
of patients with acquired immune deficiency syndrome with 
vascultic features [Klaassen et al, 1992]. Histological 
evidence of vasculitis has been demonstrated, not only in 
the above mentioned diseases, but also in Crohn’s 
[Wakefield et al, 1989; Wakefield et al, 1991] and, to a 
lesser extent in UC [Murch et al, 1992], thus, suggesting 
an immunological link between these groups of diseases. 
The systemic vasculitides and inflammatory bowel diseases 
share common features, in that both groups are of unknown 
aetiology, have autoimmune features, have ANCA and 
anti-endothelial cell antibodies [Romas et al, 1992] in the 
sera, and can be primarily treated by immunosuppressive 
steroid therapy. The usefulness of P-ANCA, as a diagnostic 
test for Crohn‘s disease, is doubtful, due to its low 
prevalence. However, these findings seem to suggest that 
prevalence of P-ANCA in Crohn‘s may be related to colitis 
as 90% of the Crohn’s patients who were found to have 
P-ANCA had colitis. In the systemic vasculitides ANCA have 
been postulated to cause vascular injury mediated by 
respiratory bursts and degranulation of cytokine primed 
neutrophils [Falk et al, 1990]. 
ANCA have been shown, not only, to activate monocytes but 
also to play a role in their growth regulation [Ewert et 
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al, 1991]. Such mechanisms may be in operation in 
inflammatory bowel disease, and the study of patients who 
have undergone restorative proctocolectomy may help to 
further investigate the role of these autoantibodies. 
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2.5 Summary 
Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) 
have been previously demonstrated in patients with various 
forms of vasculitis, and more recently, in IBD by an 
indirect immunofluorescence technique. 
The sera of 194 patients were tested for P-ANCA :- 101 with 
UC {43 with varying grades of UC, 19 following subtotal 
colectomy and 39 following restorative proctocolectomy 
(RPC) for UC}, 40 with Crohn's disease (CD) , 5 with 
indeterminate colitis, 24 non-IBD and 24 healthy volunteers 
(controls). 
Overall the prevalence of P-ANCA in UC was 70% (71/101). 
P-ANCA was still present in the majority of patients 
following restorative proctocolectomy, 74% (29/39) where 
the mean follow-up after surgery was 1.3 years. All 5 
patients who had pouchitis following RPC were P-ANCA 
positive. By contrast only 25% (10/40) of Crohn's disease 
patients had P-ANCA, 9 of the 10 had Crohn's colitis. 
P-ANCA was not detected in controls. These results show 
that P-ANCA is more prevalent in colonic inflammatory bowel 
disease, especially UC. 
The persistence of P-ANCA in the sera over one year after 
RPC suggests that the antigen(s) is (are) not fully 
eradicated and therefore, that it is not just the colon 
that is targeted immunologically in UC. 
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3.1 Introduction 
As described in the previous chapter, autoantibodies 
against the neutrophil cytoplasm can be demonstrated by 
indirect immunofluorescence in the serum of most patients 
with ulcerative colitis, and in about one quarter of 
patients with Crohn's disease. However, the origin and 
nature of the antigen or antigens has yet to be fully 
established. ANCA can be distinguished by distinct 
immunofluorescence patterns, namely granular cytoplasmic 
ANCA (C-ANCA) and perinuclear ANCA (P-ANCA). 
In sytemic vasculitis the majority of C-ANCA are specific 
for proteinase 3 (PR3) [Goldschmeding et al, 1989; 
Goldschmeding et al, 1990; Ludemann et al, 1990] and a 
substantial proporton of P-ANCA specific to myeloperoxidase 
[Falk et al, 1988; Falk et al, 1990A; Varagunam et al, 
1991]. 
The strong association of ANCA with systemic vasculitis has 
been largely established [Frampton et al, 1990; Garrett et 
al, 1992; Savage et al, 1990; Stupp et al, 1991]. 
Proteinase3-ANCA are more commonly found in patients with 
biopsy proven Wegener's granulomatosis [Van der Woude et 
al, 1985], and myeloperoxidase-ANCA are more commonly found 
in patients with a vasculitis limited to the kidney [Falk 
et al, 1988]. These associations have been confirmed by 
other investigators [Noel et al, 1993]. 
Conversely, ANCA directed against neutrophil cytoplasmic 
antigens, other than myeloperoxidase and proteinase 3, have 
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been reported rarely in vasculitis patients [Lesavre, 
1991], but more frequently, in patients with various 
chronic conditions such as inflammatory bowel disease 
[Saxon et al, 1990; Rump et al, 1990], rheumatoid arthritis 
[Savige et al, 1991], chronic hepatic diseases [Kallenberg 
et al, 1992; Hardarson et al, 1993], several infections 
including HIV infection [Klaassen et al, 1992; Davenport, 
19923. Rare ANCA antigen specificities to elastase, 
lactoferrin and CAP 57 have been observed in a few patients 
with different forms of vasculitis as recently reviewed 
[Lesavre, 1991]. 
Several independant investigators recently, have reported 
that the neutrophil antigens in inflammatory bowel disease 
are not myeloperoxidase or proteinase 3 [Saxon et al, 1990; 
Cambridge et al, 1992], and that inflammatory bowel disease 
ANCA are directed against different, as yet unknown, 
antigens. This prompted me to carry out the following 
studies, in order to determine antigen specificity of ANCA 
found in inflammatory bowel disease. 
3.2 Aims 
The aims of the following study were to determine the 
specificity of ANCA using:- 
1) purified neutrophil antigens (enzymes) 
2) using sonicated neutrophil protein. 
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3.3 Methods 
3.3 1. Neutrophil Antigen determination using enzyme linked 
immunosorbent assay (ELISA) 
The method for this ELISA previously had been validated by 
the Dept. of Renal Medicine, University of Birmingham, 
using test sera in patients with systemic vasculitis 
[Varagunam et al, 1991]. The following purified neutrophil 
granule enzymatic components were obtained commercially: 
1. lactoferrin (Sigma - human milk) 
2. cathepsin G (BDH - human neutrophil) 
3. myeloperoxidase (Sigma - human neutrophil) 
4. elastase (BDH - human neutrophil) 
5. lysosyme (Calbiochem - human neutrophil) 
6. enolase (BDH - human neutrophil) 
7. ß-glucoronidase (Sigma - bovine liver) 
The immunoplates were coated with the antigen at a 
concentration of 10 overnight at 4°C for 16 hours. The 
plates were washed, then blocked with 2% bovine serum 
albumin in PBS-Tween for one hour at 37°C. All washes 
subsequently were carried out with saline-Tween. Test sera 
diluted 1 in 10, were incubated on the plate for one hour 
after washing. Alkaline phosphatase conjugated anti-human 
IgG was incubated for one hour at 37° C. After washing 
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alkaline phosphatase Substrate was placed on the plate and 
incubated for 15 minutes at 37°C, before reading the plate 
at 405nm. 
Optical density (OD) readings were plotted against the 
numbers of control and test sera for the various antigens. 
3.32 SDS-Page Electrophoresis, Western Blotting with 
immunodetection 
3.32 1 Preparation of neutrophils 
Neutrophils for all studies were isolated from fresh whole 
blood using discontinuous density gradients of Percoll 
(Pharmacia, UK) . Density gradient centrifugation is an 
established method for the separation and purification of 
cells, making use of differences in the size and density of 
blood cells, to separate them under reasonably mild 
conditions. 
Percoll is a silica sol coated with polyvinyl-pyrrolidine 
(PVP), and is virtually free from unbound PVP [Pertoft et 
al, 1978]. It has a very low osmolality (<23 mOs/kg , is 
thought to be non-toxic to cells [Kurnick et al, 1979; 
Pertoft et al, 1977] and does not affect cell morphology 
[Schumacher et al, 1978]. Neutrophil function may be 
influenced by cell isolation procedures [Fearon et al, 
1983; Haslett et al, 1985]. In comparison to neutrophils 
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separated on Percoll gradients, those separated on, for 
example, Ficol-Hypaque gradients show spontaneous change of 
cell shape, reduced chemotactic responsiveness and 
increased release of Superoxide anion and lysosomal enzymes 
[Haslett et al, 1985]. 
3.322 Cell isolation 
Fresh venous blood was collected using a sterile 21 gauge 
needle and syringe into tubes containing 20 units of 
heparin per ml. 
Gradient 
An isoosmotic gradient stock solution of Percoll was made 
by adding 1 part 1.5M saline (density 1.058 g/ml) to 9 
parts Percoll (density 1.130 g/ml, manufacturer's data). 
The density of the stock Percoll was calculated from the 
formula : 
(volume x density of Percoll) + (volume x density of diluting medium 
(volume of Percoll) + (volume of diluting medium) 
= 1.123 g/ml 
Stock Percoll was diluted further with 0.15M saline 
(density 1.009g/ml) to densities of 1.070 g/ml [Giddings et 
al, 1980] and 1.097 g/ml [Jepsen et al, 1982] for the 
separation of white cells. This was done using the formula: 
Volume diluting medium = volume stock Percoll x 
(density stock Percoll) - required density) 
(required density) - (density diluting medium) 
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Cell 
six 
isolation 
mls of Percoll, density 1.097 g/ml, were placed into a 
sterile universal container, then 4 mls Percoll, density 
1.070 g/ml, were layered carefully on top, taking care not 
to cause mixing at the interphase. This was done with a 
sterile syringe fitted with a wide bore needle, keeping the 
tip against the wall of the tube just above the surface of 
the liquid. Five mls of blood were diluted with an equal 
volume of phosphate buffered saline, and carefully layered 
on top of the Percoll in the same way. The tube was 
centrifuged at 200g for 25 minutes, resulting in the 
isopycnic banding of cells at the relevant interphases. 
The pellet at the bottom of the tube consisted of red 
cells; granulocytes were suspended between the two layers 
of Percoll; mononuclear cells (monocytes and lymphocytes) 
were suspended above the 1.070 g/ml density Percoll layer. 
The granulocytes were removed with a pipette and washed 
twice with Dulbecco‘s B phosphate buffered saline (PBS) , 
centrifuging at 1500g for 10 minutes after each wash. 
Remaining erythrocytes were lysed by hypotonic shock 
treatment, by adding 9 parts sterile distilled water, 
followed immediately by 1 part 10x PBS, and then 
centrifuging for 10 minutes. 
Neutrophils were counted with an equal volume of white cell 
staining fluid (appendix A) and counted in an improved 
Neubauer chamber. The cells were resuspended in PBS and all 
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neutrophil suspensions were, at least, 95% pure, the 
remaining cells being contaminating eosinophils, basophils 
and, rarely, monocytes. 
Preparation of sera 
All test sera used were obtained fresh from venous blood, 
which was allowed to clot prior to centrifugation at 1500g 
for 10 minutes. The serum supernatant was transferred to 
labelled sterile tubes. 
3.323 Neutrophil sonication 
Neutrophils were resuspended in sodium acetate (0.2 M, pH 
4.2), in a 2 ml glass bijoux. 
The sonicator machine in the Cancer Research Laboratories, 
Birmingham was employed for the next step. Sonication was 
performed for 10 minutes, in bursts of 1 minute with 15 
second intervals, with the sample sitting in ice at 0°C. The 
suspension was made up to 5ml with sodium acetate buffer, 
and centrifuged at 8000g for 10 minutes at 4°C. 
The supernatant containing mainly the neutrophil 
cytoplasmic components was removed using a pipette. The 
protein concentration of the supernatant was assessed using 
the Lowry technique, after which it was aliquoted into 
ependorfs and stored at -80°C. The remaining pellet was 
resuspended in sodium acetate buffer, and examined under 
the microscope to assess the efficacy of sonication. 
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A test ELISA was carried out on all neutrophil sonicated 
suspensions (coating plate at 10 using known P-ANCA 
sera, to ensure presence of neutrophil antigens in the 
sonicate. 
3.324 Gel Electrophoresis 
In electrophoresis, the migration of proteins is dependant 
largely upon the charge, size and shape of the molecules. 
However, in the presence of sodium dodecyl sulphate (SDS), 
proteins bind the SDS, become negatively charged and have 
a similar charge:weight ratio. When SDS coated proteins are 
placed in an eletric field, their spatial separation will 
depend only upon their size and shape. By varying the 
concentration of the polyacrylamide gel, used as the medium 
for the electrophoretic separation, different resolution 
ranges of molecular weight may be obtained. Proteins may be 
fractionated in the native state, but more information is 
usually obtained if the disulphide bonds are first reduced, 
allowing separation of the individual peptide chains. After 
heating to 100°C, in the presence of reducing agents and 
SDS, the proteins unfold and bind about 1.4 g SDS 
protein. The strong negative charge on the proteins thus 
means that their electrophoretic mobility will be inversely 
proportional to the logarithm of their molecular weight 
[Hudson et al, 1989]. 
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In practical terms, a stacking gel is cast on the top of 
the separating gel, this has both a lower percentage 
polyacrylamide concentration (typically between 3 - 5 % ) ,  and 
is prepared using a buffer with a slightly different 
composition. The different mobilities of chloride and 
glycine and the slow rate of entry into the separating gel, 
relative to the rate of progression through the stacking 
gel, are exploited to concentrate the proteins in a narrow 
band at the interface between the stacking and separating 
gels. This allows the variable loading of sample. 
Originally, the technique was performed in gel tubes, but 
these have almost entirely been replaced by flat gel slabs. 
Polyacrylamide gel electrophoresis (PAGE) has become a 
standard tool for the separation and purification of 
proteins. In this study, the separation of proteins in the 
neutrophil sonicate was carried out using sodium dodecyl 
sulphate Polyacrylamide gel electrophoresis (SDS-PAGE). 
The method for PAGE was carried out, as previously 
described [Laemmli, 1970; Towbin et al, 1979], using the 
Biorad Protean II xi 16cm gel tank and Biorad gel former 
(Figure 3.1) . 
Preparation of the gels was carried out using the formulae 
given in the Biorad, UK manual: 
Glass plates were thoroughly cleaned with ethanol. Two 
glass plates were clamped together with 1mm spacers and 
placed into the gel stand. The plates were pressed firmly 
down onto the rubber base, and side screws tightened to 
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obtain a water tight seal in which to pour the gel. 
Next, the separating gel (12%) (Table 3.1) and stacking 
gels (4.5%) (Table 3.2) were poured according to the 
following recipes:- 
Table 3.1. Constituents of the Separating Gel 
Table 2. Constituents of the Stacking Gel (4%) 
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TEMED 
TEMED initiates the setting process, hence, this was added 
just before the gel was poured in between the glass plates. 
After the separating gel had set, the stacking gel was 
poured and allowed to set with a 16 well comb. When the 
stacking gel had set, the comb was removed, and the wells 
were washed twice with distilled water. 
The neutrophil sonicate samples, which previously had been 
added to the sample buffer (Appendix A), were brought to 
boil to 100°C for 30 seconds, and allowed to cool for 5-10 
minutes. 
100 of the sonicate was loaded onto the wells using a 
one ml syringe with a 23 gauge needle, followed by 
electrode buffer. The maximum capacity of each well was 135 
100 of prestained molecular weight standard was 
placed in the first and last well of each gel. The gel was 
removed from the tank and placed into the gel tank, which 
was filled two thirds with electrode buffer. After filling 
the top tank with approximately 300 ml of electrode buffer, 
the electrodes were connected, and the gel was allowed to 
run until the dye front reached the bottom. 
Initially, the gel was run at 24 mA constant current 
usually for 2 hours, or until the samples reached the 
separating gel. After this, the current was increased to 30 
mA per gel constant current for approximately 5 hours, or 
until the dye front reached the bottom. Generally, with 
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fresh electrode buffer, running time was faster. 
Coomassie Blue Staining 
In order to assess the initial results of electrophoresis 
of the sonicate, the gels were stained with Coomassie Blue 
(Appendix A). The gel was stained for 3 hours, usually to 
assess both the quality and quantity of protein separation 
before each new batch of neutrophil sonicate was tested any 
further Figure 3.2. 
3.325 Western Blotting (Transfer of protein to nitrocellulose 
membrane) 
As soon as the gel had run, having marked the left hand 
bottom side of the gel, it was removed from the glass 
plates whilst "under water" in the blotting buffer, to 
prevent cracking of the gel. Filter papers, cut to size, 
soaked in blot buffer, were placed on either side of the 
gel and presoaked nitrocellulose membrane. The whole slab 
was placed in between wet pads and placed in the caskets. 
The blotting tank (Figure 3 . 3 )  was filled with blotting 
buffer (Appendix A) and the caskets were placed in them. 
The slab was placed so that the nitrocellulose membrane was 
facing the anode side. The electrodes were connected and a 
current of 500 mA and a voltage 900 V was passed for 3 
hours, for transfer of proteins to occur (Figure 3.4). 
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3.326 Immunodetection 
After the proteins were transfered (as judged by the 
transfer of the prestained molecular weight markers), the 
blot was blocked overnight in 5% non-fat milk. The next day 
the blot was cut into strips and subjected to 
immunostaining. The principle is the same as the ELISA 
method. The strips were incubated in a specially drilled 
plastic tray (Department of Physiology, University of 
Birmingham) containing 15 lanes each 1cm in width, 10 cm 
long and 1cm in depth (Figure 3.5). 
Test sera or controls were diluted 1 in 50 in 3% BSA/Tris 
saline Tween, and incubated overnight with the individual 
strips. 
The following morning, the serum sample was tipped out and 
the strip was washed 3x with PBS on an automatic rocking 
platform in 5 minute pulses. 
The strips were incubated with conjugate - ( horse radish 
Peroxidase - antihuman IgG ) 1 in 100 dilution in 3 %  BSA 
/Tris saline-Tween for 3 hours. 
Washing was carried out as described above. The Substrate 
- AEC (brick red colour) was added and bands, if present, 
would usually appear in 5 minutes. The reaction would be 
stopped with distilled water after a maximum of 20 minutes. 
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3.327 Specificity of antigenic determinants 
The above techniques enabled identification of particular 
antigens by molecular weight only. The next step was to 
evaluate the specificity of the antigenic determinants. The 
sera which revealed evidence of antibodies to neutrophil 
sonicate were all recorded, and batched together by the 
similarities obtained from the bands on the nitrocellulose 
strips. 
These sera were tested again to confirm the banding 
patterns obtained on the strips. The particular antigens 
(ie. lactoferrin MW = 77,000 kDa) were then run down the gel 
at 1 in conjunction with the prestained molecular 
weight standards. The proteins were transfered onto 
nitrocellulose membrane by Western blotting, blocked with 
milk and cut into strips, as described above. 
These strips were incubated with IgG (H + L) sheep 
anti-lactoferrin antibodies, followed by washing x3 with 
PBS, followed by addition of IgG (H+L) pig anti-sheep HRP 
antibody. The Substrate AEC was added to obtain the colour 
precipitate. The antigens determined from neutrophil 
sonicate by molecular weight were compared, and confirmed 
to be particular neutrophil enzymes ie. lactoferrin [Peen 
et al, 1993]. 
Sheep anti-cathepsin G antibody (H + L), anti-enolase (H +- 
L), anti-elastase (H + L), anti-myeloperoxidase (H + L), 
and anti-lysozyme were used similarly to confirm presence 
of the detected neutrophil enzymes (antigens). 
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Summary illustrating the two procedures 
1.neutrophil sonicate (containing antigen) on 
nitrocellulose membrane 
test or control serum 
HRP conjugated sheep antihuman IgG 
AEC (red precipitate) 
2.pure antigen (ie lactoferrin) 
sheep anti-lactoferrin antibody 
HRP conjugated pig anti-sheep IgG 
AEC (red precipitate) 
All the antibodies described in this chapter, were kindly 
donated from The Binding Site (BDH), Birmingham. 
3.4 Statistics 
Comparisons of the prevalence and titres of ANCA in 
different subjects were made using the Fisher's exact test, 
Chi squared analysis and student's t-test. The Wilcoxon - 
Rank test was used to determine statistical significance of 
the optical density values for the neutrophil purified 
antigen ELISA. Optical density values, greater than the 
95th percentile above the control mean, were taken as 
significantly different. 
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3.5 Results 
In total, there were 71 out of 101 (70.2 % )  patients with 
P-ANCA detected by indirect immunofluorescence. None of 
ANCA negative sera gave a positive value using the ELISA 
method. 
The optical density values obtained for the individual 
commercially obtained antigens are shown in Figures 3.6 - 
3.12. Tables 3.3 and 3.4 show a quantitative figure for the 
antigens using the 95th percentile of healthy controls as 
a cut-off. 
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Ulcerative colitis 
Of the 71 patients with P-ANCA, 21 antigenic bands, ranging 
from 23-95 kDa, precipitated on the nitrocellulose strips. 
Only 18 antigenic bands (Figure 3.13) could be matched 
corresponding to known neutrophil antigens in UC. In 3 sera 
antigens between 60-65 kDa could not be matched on any 
known neutrophil enzyme. 
Table 3.3 shows antigens detected by Western Blot and ELISA 
in UC. 
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Crohn's disease 
In total, there were 10 out of 40 (25.0 % )  patients with 
P-ANCA detected by indirect immunofluorescence. Of these 10 
patients with P-ANCA, 5 antigenic bands were detected:- 3 
77 kDa (lactoferrin), one 40kDa and the other 55 kDa. The 
40kDa and 55kDa antigens could not be matched to any 
neutrophil a-granule enzymes. 
The following matched antibodies which were detected are 
shown in the following table:- 
Table 3.4 Western Blot and ELISA detection of ANCA antigens 
in Crohn's disease 
In both UC and Crohn's bands were not detected in any of 
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the P-ANCA negative patients and only one band was detected 
per patient sera. 
In essence, from this study the major antibody system which 
has emerged in UC and Crohn's disease is anti-lactoferrin 
antibody, and, to a lesser extent, anti-cathepsin G 
antibody (Figure 3.13) . 
3.6 Discussion 
In this study, I have established, with the help of 
clinical and technical staff from the Depts of Physiology, 
Infection, Immunology and Surgery, the occurence of ANCA 
directed against lactoferrin and cathepsin G in 
inflammatory bowel disease. 
Several different types of autoantibodies have been 
described in inflammatory bowel disease [Nielsen et al, 
1983; Snook et al, 1989; Saxon et al, 1990; Duerr et al, 
1991; Broberger et al, 1959; Perlmann et al, 1967; Das et 
al, 1984; Skogh et al, 1982; Skogh et al, 1986; Chapman et 
al, 1986; Snook et al, 1991]. Although none of the 
autoantibodies have been proved to be of pathogenic 
significance, it has been shown in both ulcerative colitis 
and Crohn's, that IgG and complement can be present on the 
apical surface of enterocytes, in vivo [Green et al, 1975; 
Hallstensen et al, 1990], possibly indicating a pathogenic 
role for anti-epithelial/antibrush border antibodies. 
In this connection, and considering the high frequency of 
anti-lactoferrin antibodies found in the present study, it 
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is interesting to note that lactoferrin has been reported 
to bind the intestinal brush border via a specific receptor 
[Davidsson et al, 1988]. 
It is possible that many of the anti-microbial antibodies 
described in inflammatory bowel disease and other 
inflammatory disease states, may, in fact, be reflections 
of immunisation against microbial heat shock proteins. 
These have been implicated in the pathogenesis of several 
autoimmune disease states [Winfield et al, 1991], and may 
induce anti-lactoferrin antibodies [Perlmann et al, 1967]. 
Lactoferrin 
Lactoferrin is an iron binding protein that occurs 
abundantly, not only in the specific granules of 
granulocytes [Furmanski et al, 1990], but also in tears, 
milk and secretions at mucosal surfaces [Wang et al, 1984; 
Magnuson et al, 1990; Kuizenga et al, 1987]. Raised levels 
of circulating lactoferrin are seen during active 
inflammatory bowel disease [Adeyami et al, 1990]. It exerts 
antibacterial effects by depriving bacteria of iron 
required for growth, and it has anti-inflammatory 
properties - for example, by preventing complement 
activation through inhibition of classical C3 convertase 
[Kievits et al, 1985]. Lactoferrin can also prevent the 
formation of hydroxyl ions by iron binding [Kuizenga et al, 
1987]. Lactoferrin may thus be of great importance as a 
non-specfic anti-phlogistic defence factor at the primary 
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immunological barriers. It has been shown experimentally 
that binding of lactoferrin to anti-lactoferrin antibodies 
increases the amount and duration of hydroxyl radical 
formation by granulocytes [Britgan et al, 1989]. 
Hypothetically, antilactoferrin autoantibodies could, by 
counteracting the anti-inflammatory effects of lactoferrin, 
aggravate and prolong inflammation induced by several 
different mechanisms, and the antibodies, may, therefore 
have pathogenic significance, even though their occurence 
does not correlate with disease activity. Anti-lactoferrin 
antibodies may also have pathogenic effects by activation 
of primed granulocytes infiltrating the gut mucosa or 
adhering to vessel walls, in analogy with the other types 
of ANCA [Skogh et al, 1991; Charles et al, 1991; Falk et 
al, 1990b]. 
In addition, mucosal lactoferrin/anti-lactoferrin complexes 
may stimulate intestinal goblet cells to excessive mucus 
sedcretion, as do other immune complexes [Walker et al, 
1977]. 
On the other hand, the occurence of anti-lactoferrin 
antibodies could be an epiphenomenon, but not one which is 
based solely on colonic inflammation, since ANCA do not 
occur in other diarrhoea1 illnesses, where there is colonic 
inflammation [Duerr et al, 1991]. The fact that the 
individual types of ANCA were found only in a minority (< 
30%) of sera tested is an argument in favour of this. 
Alternatively, consumption of circulating antibodies cannot 
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be ruled out in the seronegative instances. 
The origin of anti-lactoferrin autoantibodies is unknown. 
Although bovine and human lactoferrin have molecular and 
antigenic similarities [Magnuson et al, 1990], immunisation 
of experimental animals with bovine lactoferrin seldom 
seems to result in cross immunisation against human 
lactoferrin [Wang et al, 1984]. 
The lack of correlation between levels of anti-human 
lactoferrin and anti-bovine lactoferrin [Peen et al, 1993] 
contradicts the hypothesis that cross immunisation against 
dietary bovine lactoferrin results in the appearance of 
anti-human lactoferrin autoantibodies. 
A point worth considering is the antigenic mimicry between 
the 65 kDa mycobacterial heat shock protein (HSP-65) and 
human lactoferrin, and the fact that immunisation against 
HSP-65 results in the production of anti-lactoferrin 
antibodies [Winfield et al, 1991]. Mycobacterial infection 
and immunisation against mycobacterial antigens/HSP-65 have 
been implicated in several autoimmune disease states, both 
experimental and clinical [Esaguy et al, 1991; Barnes et 
al, 1990; Lydyard et al, 1991; Shoenfield et al, 1988; 
Hampson et al, 1988]. It is also interesting to note that 
there have been reports of anti-HSP-65 antibodies in 
Crohn’s disease [Walker et al, 1977]. 
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ANCA directed against Cathepsin G, myeloperoxidase, enolase and 
elastase. 
Cathepsin G is a chymotrypsin like protease found in the 
primary granules of neutrophils. Antibodies to Cathepsin G 
have been reported in both ulcerative colitis and Crohn's 
disease [Halbwachs et al, 1992] however the frequencies 
reported vary a great deal. In our study Cathepsin G was 
detected in only 4/101 patients (4%) with UC and 2/40 (5%) 
with Crohn's disease. 
Antibodies to other antigens were detected only in 
ulcerative colitis sera (1/101 had anti-MPO, 1/101 had 
anti-elastase, 1/101 had anti-enolase) . This 
multispecificity of ANCA in inflammatory bowel disease, 
which has been shown by Western blotting suggests further 
immunological differences within the same disease and 
perhaps, the time has now come to grade these diseases not 
just clinically, but also immunologically. Only then shall 
we be able to classify comprehensively the symptom complex 
which has been termed chronic inflammatory bowel disease. 
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3.7 Summary 
The antigens on the neutrophil which correspond to ANCA in 
inflammatory bowel disease have yet to be fully identified. 
In systemic vasculitis these antigens have been found to be 
enzymes in the a-granules of the neutrophils. 
The aims of this study were to determine the specificity of 
ANCA using 1) purified neutrophil antigens (enzymes) 2) 
using sonicated neutrophil protein. 
Methods: 1) Immunoplates were coated with commercially 
obtained purified neutrophil enzymes: lactoferrin, 
cathepsin G, myeloperoxidase, elastase, enolase, lysozyme 
and ß glucoronidase. Test and control sera were added 
followed by alkaline phosphatase conjugated anti-human IgG 
and Substrate. The plates were read at 492 nm and results 
plotted. Values above the 95th percentile of normal 
controls were regarded as positive. 2) Sonicated neutrophil 
protein was applied to a SDS-PAGE column. The separated 
proteins were then tansferred to nitrocellulose membrane 
using Western Blotting. The membrane was cut into strips 
and diluted sera added, followed by HRP-conjugated anti- 
human IgG. AEC (brick red) was used as the Substrate. The 
antigens were determined using molecular weight 
corresponding to the markers on the membrane. 
i)Table 3.5. Using commercially purified neutrophil antigens the 
following results were obtained. 
ii)Table 3.6. Using neutrophil sonicate the following results were 
obtained. 

8 4  
Elisa was a more sensitive method for the detection of 
neutrophil antigens in IBD ANCA positive sera. IBD ANCA 
positive sera recognize different antigens which appear to 
be distinct from the commonly found antigens in systemic 
vasculitis namely proteinase 3 and myeloperoxidase. 
Further studies using purified neutrophil enzymes may help 
to elucidate the unidentified antigens in ANCA positive 
sera. 
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Target antigen identification of ANCA using confocal scanning laser 
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4.1 Introduction 
The autoantigen(s)of ANCA in inflammatory bowel disease 
have yet to be fully identified. There have been two 
reports to date stating that lactoferrin [Peen et al, 1993] 
and Cathepsin G [Halbwachs et al, 1992] are the main target 
antigens, but these have been conflicting. However, both 
agree in the discussion parts of their papers that several 
other, as yet, unidentified antigens exist. 
It is now 4 years since ANCA were first described in IBD 
[Saxon et al, 1990] and yet, the target antigens have not 
been found. This prompted me to look back to see whether I 
could identify the exact anatomical and morphological site 
of ANCA binding on the neutrophil. 
I initially set out considering electron microscopy, but, 
was advised that this could not identify the fluorescence 
markers specifically. The light microscope did not provide 
enough resolution and therefore, I used confocal scanning 
laser microscopy. 
4.11 Principles of confocal scanning laser microscopy 
An ordinary light microscope presents the operator with a 
2-D image, consisting of an in-focus and an out-of-focus 
region of the specimen. In order to obtain greater 
resolution (3-D) of the specimen, several photographs have 
to be taken at different focus settings and at different 
levels of section. 
This process is time consuming and has several technical 
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difficulties. A promising, relatively new method for 3-D 
studies is confocal microscopy [Carlsson et al, 1987]. 
The basic principle is that the specimen is illuminated one 
point at a time, and the detector only registers light 
emanating from the focussed illuminated point (Figure 4.1) . 
Simultaneous viewing of a large number of points in this 
way enables the operator to view a section in real time, 
through the eyepieces of the microscope. A computer is used 
in conjunction, to process digitized images in such a way 
that out of focus information is filtered out [Agard et al, 
1983; Erhardt et al, 1985]. 
The point illumination and point detection scheme results 
in imaging properties that are different from those of an 
ordinary light microscope. One such difference is that the 
resolution is improved and another is that a very 
pronounced depth discrimination is obtained. This means 
that different depth layers can be studied much more 
clearly, since no out of focus information is superimposed 
on the image. 
Thus, this technique of recording the entire structure of 
the fixed neutrophil after application of ANCA with an 
immunofluorescence tag, refocusing the microscope between 
successful images, would allow a 3-D image of high 
resolution to be created. 
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4.2 Aims 
The aims of this study were to determine the target site of 
ANCA ie. the exact morphological site of antigen-antibody 
binding which gives rise to the P-ANCA immunofluorescence 
patterns in IBD using confocal scanning laser microscopy. 
4.3 Patients and methods 
Sera from 125 patients (101 with UC and 24 healthy 
controls) were tested for the presence of ANCA, using the 
method of indirect immunofluorescence, as described in 
chapter 2. The disease activity of the patients with 
ulcerative colitis was assessed in a modified form, as 
described in chapter 2 [Kodner et al, 1990]. However, on 
this occasion the neutrophil nuclei were further stained 
with ethidium bromide. Ethidium bromide is a nucleus 
specific dye. 
Table 4.1 Distribution of UC patient sera. 
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Method of indirect immunofluorescence: - 
HEALTHY NEUTROPHILS ISOLATED & FIXED WITH ETHANOL OR 
FORMALDEHYDE ONTO GLASS SLIDES 
SLIDES INCUBATED WITH TEST OR CONTROL SERA (1 IN 20) 
FOR 30 MINUTES 
WASHING 
INCUBATION WITH FITC CONJUGATED ANTI-HUMAN IgG 
FOR 20 MINUTES 
WASHING 
INCUBATION WITH ETHIDIUM BROMIDE (1 IN 1 O) 
WASHING 
SLIDES FIXED WITH DABCO 
READ ON LEITZ ORTHOPLAN IMMUNOFLUORESCENCE MICROSCOPE 
BY MYSELF AND RON STOKES (IMMUNOLOGIST) 
The slides with the brightest immunofluorescence patterns 
of P-ANCA and C-ANCA were read on the confocal laser 
microscope with the help of Gerald Johnson, Department of 
Immunology, University of Birmingham. The principle has 
been described in Figure 4.1. 
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4.4 Results 
The P-ANCA and C-ANCA patterns were indistinguishable on 
slides in which the neutrophils were fixed with 
formaldehdye, thus confirming previous studies which showed 
that these patterns are a result of the way in which 
neutrophils are fixed [Falk et al, 1988]. 
The P-ANCA and C-ANCA patterns were distinguishable by 
ethanol fixation of neutrophils, and overall clarity was 
better. ANCA was not detected in any of the healthy 
controls. 
Table 4 . 2  ANCA distribution in patients with ulcerative 
colitis. 
4.41 3-D imagng of the neutrophil in different vertical planes using confocal imaging 
Figure 4 . 2  shows the image obtained for the P-ANCA pattern on 
ethanol fixed neutrophils, after staining the nucleus with 
ethidium bromide, using conventional light microscopy. One can 
see that it would be very difficult to interprete where exactly 
the immunofluorescence is emanating ie. from within the nucleus 
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or just outside. 
Figure 4 . 3  shows separation of the digital images obtained on 
the confocal microscope of the nuclear stain from the 
immunofluorescence stain. 
The computer attached to the confocal microscope was used to 
assess the amount of overlap between the red and the yellow. 
This, after examination of all the P-ANCA sera, revealed that 
>95% of the immunofluorescence was in fact intra-nuclear. 
Figure 4 . 4  shows the images obtained when the confocal 
microscope was focussed from the level of the glass slide 
vertically upwards at cuts of approximately 0.1 microns. This 
showed that the maximum area of immunofluorescence emanated 
from the centre area of the neutrophil nucleus. 
Having stored the information on the hard disk of the computer 
one could then assess the maximum area of immunofluorescence 
by looking at the neutrophil in cross-section ie., by looking 
at the spread out neutrophil on the slide from the side :- 
Figures 4 . 5  and 4 . 6 .  Using this technique again, I was able to 
determine that the maximal area of immunofluorescence emanated 
from the nucleus. 
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4.5 Discussion 
The most common and original screening method for detection of 
ANCA is still the indirect immunofluorescence technique on 
ethanol fixed human neutrophils [Gross et al, 1990]. Fixation 
of the cells by ethanol allows discrimination between the 
different fluorescence patterns : C-ANCA and P-ANCA. P-ANCA is, 
indeed, an artefact of alcohol fixation [Falk et al, 1988]. If 
fixation is done in formaldehyde, which prevents the 
translocation of basic (positively charged) proteins to the 
negatively charged nucleus, it is impossible to discrimminate 
between C-ANCA and P-ANCA (both exhibit the same cytoplasmic 
staining pattern). However, formaldehyde fixation enables 
distinguishing between ANCA and granulocyte specific 
antinuclear antibodies (GS-ANA). GS-ANA, in contrast to ANCA, 
exhibit a nuclear fluorescence pattern on formaldehdye fixed 
neutrophils. Further exclusion of GS-ANA is possible by testing 
the sera on Hep2 cells {The Binding Site, Birmingham}. 
My findings, in this study, that >95% of the antibody binding 
occurs within the nucleus has led to several possibilities:- 
a).neutrophil fixation with ethanol draws the antigens into the 
nucleus whereas formaldehyde fixtion of the neutrophils does 
not. 
b) .Are the antigens drawn to the nucleus other than by a charge 
mechanism following fixation with alcohol? 
c).Are there antigens for ANCA actually within the nucleus 
ie.histones? 
d).Is this just simply an epiphenomenon? 
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I believe that the most likely reason is that alcohol fixation 
results in the inward migration of basic proteins by a charge 
mechanism. [Falk et al, 1988]. 
The brightness of immunofluorescence was not related to disease 
activity in UC on confocal microscopy, and this again raises 
two important points for discussion: 
i). Are ANCA in IBD a different group of antibodies entirely 
since they do not correlate with disease activity as has been 
shown in patients with, for example, Wegener's granulomatosis 
[Van der Woude et al, 1985]. 
ii).Following total colectomy the titres of ANCA should fall, 
as the target organ has been removed by colectomy, however, 
this is not the case. In systemic vasculitis titres of ANCA 
fall with remission of the disease [Van der Woude et al, 1985; 
Rasmussen et al, 1988]. If one is to postulate that ANCA are 
involved in the persistence of disease activity then the titres 
should fall with time. However, if ANCA are present, as a 
result of the loss of immunoregulation at some stage, then one 
can explore the possibilty of correcting this immunoregulatory 
defect in a select group of patients who have undergone 
restorative proctocolectomy, to assess new emerging 
immunoregulatory agents, such as cytokines or their inhibitors. 
ANCA seem to be unique to IBD when compared to systemic 
vasculitis in that: 
i) they do not correlate with disease activity 
ii)titres do not relate to remission of disease 
iii)they have different antigenic determinants 
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4.6 Summary 
P-ANCA have been described to occur in UC, but the antigen(s) 
on the neutrophil have yet to be determined in this disease. 
The aims of this study were to localise the binding of ANCA 
onto alcohol fixed neutrophils, using confocal scanning laser 
microscopy. 
A hundred and one sera from patients with UC were tested for 
ANCA, and of these 71 had P-ANCA. P-ANCA were further stained 
with ethidium bromide to identify the full extent of the 
neutrophil nucleus. Reading was then carried out on the 
confocal laser microscope. 
This revealed that in P-ANCA sera the maximum 
immunofluorescence emanated from within the nucleus ( 9 0  % )  in 
all cases which were studied. The immunofluorescence was 
located around the circumference within the nucleus, and not 
from the perinuclear area (outside the nucleus), as seen on 
conventional light microscopy. 
These findings seem to suggest that the ANCA antigens are 
either located within the nucleus, or that the process of 
alcohol fixation of the neutrophils possibly draws these 
antigens by a charge mechanism into the nucleus, without 
causing too much architectural disturbance of the neutrophil. 
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5.1 Introduction 
Anti-endothelial cell antibodies (AECA), were originally 
implicated as a pathogenic factor in the vascular injury 
induced in patients with systemic lupus erythematosus 
[Cines et al, 1984]. Since then they have been reported to 
occur in Kawasaki syndrome [Leung et al, 1986; Leung et al, 
1987], haemolytic uraemic syndrome [Leung et al, 1988], and 
rheumatoid vasculitis [Heurkens et al, 1989; Quadros et al, 
1990]. Recently, several studies have reported that sera 
from 30-60 % of patients, with polyarteritis and Wegener's 
granulomatosis, contain antibodies to endothelial cells 
[Ferraro et al, 1990; Frampton et al, 1990; Savage et al, 
1991]. 
The role of AECA in the vasculitic disorders and mechanisms 
by which vascular injury may be brought, about are well 
documented [Cines et al, 1984; Leung et al, 1986; Leung et 
al, 1987; Leung et al, 1988]. Although vasculitis has been 
documented in inflammatory bowel disease, very little is 
known of the mechanisms involved. [Murch et al, 1992; 
Wakefield et al, 1991]. 
Anti-neutrophil cytoplasmic antibodies (ANCA) have been 
described in many vasculitic disorders and also more 
recently in inflammatory bowel disease [Saxon et al, 1990; 
Rump et al, 1990; Cambridge et al, 1992; Siebold et al, 
1992]. In systemic vasculitis ANCA have been postulated to 
cause vascular injury mediated by respiratory bursts, and 
degranulation of cytokine primed neutrophils [Falk et al, 
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1990B]. ANCA have also been shown to not only activate 
monocytes, but also to play a role in their growth 
regulation [Ewert et al, 1991]. In chapter 2, I showed that 
removal of the primary target site (the colon) by total 
colectomy has no apparent effect on the prevalence of ANCA, 
suggesting further that it is not just the colon which is 
targeted immunologically in this disease [Patel et al, 
1994 ]. 
AECA and ANCA are thought to be two important antibody 
systems in the systemic vasculitides. AECA have been 
recently described in IBD [Romas et al, 1992, Stevens et 
al, 1993] however, relatively little is known of this 
antibody in this group of diseases. 
5.2 Aims 
The aims of this study were to investigate the role of AECA 
in inflammatory bowel disease and especially, to assess the 
effect of total colectomy on the prevalence of the 
antibody. 
NB. This study was started in 1991 before studies of the 
existance of AECA in IBD were reported [Romas et al, 1992; 
Stevens et al, 1993]. 
5.3 Patients and methods 
Sera from the following group of patients were collected 
and stored at -80°C : ulcerative colitis, n = 41; ulcerative 
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colitis who had undergone total restorative 
proctocolectomy, n=30; Crohn's disease, n=30 and 34 healthy 
controls. The diagnosis in all cases was established by 
prior clinical and histological features obtained on 
biopsies, or from gross specimens taken at the time of 
colectomy. None of the patients had any previous evidence 
of other vasculitic disorder. The disease activity of 
patients with ulcerative colitis was assessed using a 
modified score [Kodner et al, 1990] and in Crohn's disease 
using the Crohn's disease activity index (CDAI) [Harvey et 
al, 1980] 
5.31 Endothelial cells 
These were obtained from fresh human umbilical veins by 
collagenase digestion. Cells between passes two and four 
were used for the experiments. The cells were coated in 
flasks precoated with 1% gelatin in M199 + 20 % human 
serum, 0.02 mmol/l glutamine, 15 mg/ml endothelial cell 
growth factor, 50 U/ml of heparin, 83 IU/ml penicillin, and 
83 streptomycin. For the experiments endothelial 
cells were detached with collegenase (1 mg/ml), seeded in 
microtitre plates at a concentration of 2 x in 
endothelial culture medium containing 20 % FCS in place of 
human serum and cultured until confluent. The cells were 
confirmed to be endothelial cells by immunofluorescence 
staining with antibody to Factor VIII (RAG Dako). 
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5.32 Antibodies to endothelial cells 
These were detected by an ELISA [Hashemi et al 1987] with 
minor modifications. Endothelial cells were fixed with 1% 
paraformaldehyde for 10 minutes. After blocking for 1 hour 
in 0.1 M phosphate buffered saline (PBS)/ 2% bovine serum 
albumin (BSA) (also used as the diluent for subsequent 
steps) at 37 ° C, sera from patients and controls were added 
at a dilution of 1/20 and incubated for one hour. After 
washing, horseradish Peroxidase conjugated sheep anti-human 
IgG(Fc) was added at a dilution of 1/10,000 followed by 
o-phenylenediamine in 0.05 M citrate buffer (2.2 x M 
final concentration) containing 6 x 10 -3 % The reaction 
was stopped with 20% after 15 minutes, and the optical 
density (OD) of the wells read at 492 nm. 
5.33 Inhibition ELISA to test for the specificity of the AECA assay 
Serum taken from a patient with ulcerative colitis, which 
was positive for AECA, was mixed at a dilution of 1/80 with 
an endothelial cell sonicate in a concentration range 
0.07-2.5 and the AECA assay was performed as 
described above. The percentage inhibition was derived from 
the formula: 
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5.34 Antineutrophil cytoplasmic antibodies 
ANCA titres were measured by indirect immunofluorescence, 
as previously described [Lee et al, 1990]. Briefly, 
neutrophils were isolated on Percolll gradients and the 
cytocentrifuge preparation was susequently fixed with 95 % 
ethanol onto slides. The slides were then incubated for 30 
mins with test sera diluted 1 in 20 in PBS. After washing 
incubation was carried out with FITC conjugated anti-human 
IgG for another 30 mins. After washing the slides were 
mounted with DABCO (fixing reagent) and examined under the 
Leitz fluorescence microscope at 50 x magnification. 
Depending on the brightness of immunofluorescence staining, 
the reactions were graded into negative ( - ) ,  weak (+) ,  
positive (++), and strong (+++). 
A n t i- M P O  antibodies 
Anti-MPO antibodies were detected by an ELISA, as 
previously described [Lee et al, 1990]. Briefly, Nunc ELISA 
plates were coated with MPO at a concentration of 10 
micrograms/ml in 0.05 M bicarbonate buffer pH 9.6 for 16 
hours at 37° C. Sequential incubations of the following were 
performed for 1 hour at 37° C. 0.1 M PBS/0.05 % Tween 20 
(v/v) was used as diluting buffer, and the wells were 
washed between each incubation with 0.15 M NaCl/0.05% Tween 
20 (v/v). (1) serum diluted 1/20 (2) sheep antihuman IgG 
(Fc) (Binding Site, Birmingham) at a dilution of 1/800 
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( 3 )  p-nitrophenyl phosphate (1mg/ml) in 10 % diethanolamine 
pH 9.8. The OD of the wells was read at 405 nm. 
5.35 Adsorption studies to remove ANCA 
This was done in order to determine whether ANCA and AECA 
were two separate antibody systems. Human group O +ve 
neutrophils were isolated and fixed in ethanol onto plates 
as previously described [Savage et al, 1991]. Samples of 
serum (100 were incubated for 60 min with 5 x fixed 
neutrophils. Supernatants were then harvested and adsorbed 
against a second batch of cells. Before use, protein 
concentrations of the samples were adjusted to those of the 
unadsorbed samples. The samples were then tested for the 
presence of AECA, as described above. 
5.36 Statistics 
Differences between the various disease groups of patients 
and healthy controls were analysed by the Wilcoxon rank sum 
test. The significance of the prevalence of AECA with ANCA 
was determined using the Mann-Whitney test. 
5.4 Results 
5.41 IgG anti-endothelial cell antibodies 
The inter-assay and intra-assay coefficients of variation 
for the AECA assay was 9 . 1  % and 4.2 % respectively. IgG 
106 
AECA levels in the control sera were not normally 
distributed, so the 95th percentile of 34 healthy control 
sera was used to define the upper limit of normal. The 
distribution of AECA in the various patient groups is shown 
in Figure 5.1. In ulcerative colitis and Crohn's disease 
AECA levels did not correlate with disease severity. 
In the test sera, AECA were found in 15 out of 41 patients 
with ulcerative colitis, 12 out of 30 patients who had 
undergone restorative proctocolectomy and 6 out of 30 
patients with Crohn's disease. Overall, 3 3  patients out of 
101 with inflammatory bowel disease had detectable AECA 
(Table 5.1). AECA was not detected in any of the control 
sera taken from healthy patients. 
Table 5.1. Number of patients with AECA and ANCA in the 
disease study groups. 
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5.42 Inhibition of anti-endothelial cell antibodies with an endothelial 
cell sonicate. 
The specificity of the AECA assay was assessed by 
inhibiting the binding of AECA from a patient’s serum with 
an endothelial cell sonicate. Figure 5.2 shows maximum 
inhibition of 94% of AECA binding by 2.5 of 
endothelial cell sonicate. 
5.43 AECA and ANCA 
Table 5.1 shows the results for the 101 patients with 
inflammatory bowel disease, tested for ANCA using indirect 
immunofluorescence in relation to AECA. Table 5.2 shows the 
various gradations of brightness as seen by indirect 
immunofluorescence microscopy of positive ANCA sera. 
Table 5.2. ANCA titres measured by indirect 
immunofluorescence. 
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AECA titres were higher in sera with a positive ANCA 
(median OD = 0.20; range = 0.094 - 0.469), than in sera 
with a negative ANCA (median = O. 13; range O. 020 - 0.25) ; 
and the difference was significant, (P = 0.0001) using the 
Mann-Whitney test. Twenty seven out of the 33 patients who 
had AECA were also ANCA positive, and by contrast only 6 
out of 36 patients who were ANCA negative had a positive 
AECA. 
Anti-MPO ant ibod ies  
It is interesting to note that none of the IBD patients had 
anti-MPO antibodies, where as, in systemic vasculitis this 
represents a major antibody system. 
5.44 Adsorption studies 
The sixty-five ANCA positive sera were incubated with 
ethanol fixed normal neutrophils. After adsorption with 
neutrophils, ANCA were no longer detectable using an 
indirect immunofluorescence assay. Adsorption of ANCA from 
33 AECA positive sera slightly reduced AECA levels, from 
median 0.19 range 0.14 - 0.29 to median 0.17 range 0.14 - 
0.24. There was no significant loss of AECA activity after 
adsorption of serum with neutrophils ( p=0.09 ) .  
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5.5 Discussion 
AECA may represent one group of autoantibodies which cause 
vascular injury in systemic vasculitis. However, although 
the general consensus, at present is that they have a 
pathogenic potential. The mechanisms by which vascular 
injury and inflammation are brought about is poorly 
understood, and several hypotheses have been put forward. 
This study shows that AECA exists in UC, a disease, which 
has not previously been reported to exhibit classical 
vasculitic features. The hypothesis that anti-MPO 
antibodies bind to endothelium bound MPO, and that this may 
be a possible mechanism for endothelium damage in systemic 
vasculitis [Varagunam et al, 1991], cannot be applied to 
IBD since this study together with other studies did not 
demonstrate anti-MPO antibodies in the sera of patients 
with IBD. 
The pathogenic potential of AECA has been studied most 
extensively in Kawasaki disease [Leung et al, 1986; Leung 
et al, 1987]. Kawasaki disease is a necrotizing arteritis 
that affects children predominantly and occurs worldwide. 
Clinical manifestations include fever, polymorphous 
erythematous rash, diffuse mucosal inflammation, 
non-supparative lymphadenopathy, and in some patients, 
cardiac failure due to coronary arteritis. 
Leung and associates have studied autoimmune events in 
Kawasaki disease that appear to be involved in the 
pathogenesis of vasculitis. They have observed that 
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patients with Kawasaki disease have circulating antibodies 
which react with cytokine inducible non-major histocom- 
patibility complex (MHC) molecules on endothelial cells, 
resulting in endothelial cell lysis in vitro. Specifically, 
they detected IgG and IgM AECA that cause complement 
mediated lysis of human umbilical and saphenous endothelial 
cells, that have been pretreated with gamma interferon, 
interleukin-1, or tumour necrosis factor. From these 
observations, a pathogenic mechanism for vasculitis in 
Kawasaki disease would entail two events: 
a. Production of AECA (possibly related to the polyclonal 
B-cell activation that occurs in patients with Kawasaki 
disease), and increased cytokine production (possibly 
related to the increased activity of CD4 T lympbocytes and 
monocytes that also occurs in Kawasaki disease). 
b.The AECA would bind to up-regulated endothelial antigens, 
and cause endothelial death and vascular inflammation. 
The above immunological mechanisms may be operating in I B D ,  
however, studies have shown that AECA cross-reacts with 
other cells. It has been shown that AECA, in patients with 
rheumatoid vasculitis and some collagen-vascular disorders, 
specifically cross-reacts with fibroblasts, and 
non-specifically to peripheral blood mononuclear cells, and 
thus, do not appear to be specific for endothelial cells 
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[Heurkens et al, 1989; Quadros et al, 1990]. This cross 
reactivity could be a possible mechanism by which abnormal 
mononuclear expression of cytokines and fibroblast 
proliferation is brought about. 
Little is known of the significance of AECA in IBD. This 
study has shown that although IBD is a completely different 
group of inflammatory diseases, there appear to be 
immunological similarities to the systemic vasculitides. 
This phenomenon is perhaps not just coincidence since ANCA 
has also been found to occur in both groups of diseases. 
Histologically, there is unequivocal evidence of vasculitis 
in Crohn's [Wakefield et al, 1991] but perhaps this is not 
so well demonstrated in UC [Murch et al, 1992. Granulomas 
are not a universal finding in Crohn's disease and a 
spectrum of vascular inflammation occurs in Crohn's disease 
ranging from a lymphocyte-predominant pattern to granulo- 
matous vasculitis with giant cell formation [Wakefield et 
al, 1989]. Patients with a non-granulomatous Crohn's 
disease, show a lymphocyte-predominant pattern of 
vasculitis and it is notable that this same spectrum of 
vascular inflammation is seen in Wegener's granulomatosis 
[Devaney et al, 1990]. It is also interesting to note that 
both IBD and systemic vasculitis not only share two similar 
antibody systems namely ANCA and AECA but also respond to 
immunosuppressive measures, namely steroid therapy. 
Another observation in this study was that, despite total 
colectomy for UC, AECA was still prevalent suggesting that 
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the immunological processes which initiate IBD are not 
halted by total colectomy. This observation also applies to 
the previous study on ANCA [Patel et al, 1994]. Whether 
AECA represents a cause or effect of the various vasculitic 
diseases still needs to be elucidated. 
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5.6 Summary 
Anti-endothelial cell (AECA) and anti-neutrophil 
cytoplasmic antibodies (ANCA) are known to occur in 
systemic vasculitis. While ANCA has been described in 
inflammatory bowel disease (IBD) little is known of the 
role of AECA. Steroids remain the cornerstone in the 
treatment of both groups of diseases. The aims were to 
assess the prevalence and effect of total colectomy on AECA 
in IBD. Sera from 101 patients with IBD were tested for 
AECA by an ELISA using human umbilical vein endothelial 
cells, 41 with UC, 30 with UC who had undergone restorative 
proctocolectomy, and 30 with Crohn's disease. Sera from 34 
healthy individuals were used as controls. 
Overall 33/101 patients were AECA positive :- 15/41 with 
UC, 12/30 who had undergone restorative proctocolectomy and 
6/30 with Crohn's. All 5 patients who had pouchitis were 
AECA positive. 27 out of 33 patients who had AECA were also 
found to have ANCA. Neutrophil adsorption studies of ANCA 
were performed to differentiate between ANCA and AECA. 
These results show AECA occurs as a distinct antibody 
system in IBD, and that immunological similarities of IBD 
and systemic vasculitis are not just coincidence. Despite 
total colectomy, AECA persists, suggesting continuing 
immunological processes. Colonic metaplasia in the ileal 
pouch or pouchitis may be possible reasons for this. AECA 
like ANCA represents a major antibody system in IBD which 
needs further investigation. 
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6.1 Introduction 
Circulating autoantibodies to colonic epithelial cells have 
been shown, by various techniques, in a proportion of 
patients with ulcerative colitis. The best characterised of 
these is the 'classical' anticolon antibody (Anti-EPI) with 
affinity for colonic mucopolysaccharide [Broberger et al, 
1959; Broberger et al, 1963; Wright et al, 1966; Chapman et 
al, 1986; Snook et al, 1991]. From the literature however, 
it is unclear whether cytotoxic antibody, which has been 
shown to be capable of mediating colonocyte specific 
cytotoxicity [Shorter et al, 1970; Das et al, 1984; Auer et 
al, 1988], is the same antibody as Anti-EPI. The relation 
between these two characterised antibodies, if different, 
is unclear and their importance in the pathogenesis of 
ulcerative colitis is uncertain. 
A possible target antigen for this anti-colon antibody has 
been described to be a 40kDa epithelial membrane protein 
[Das et al, 1992]. This protein is expressed not only by 
the colon but also by gall bladder and skin, possibly 
providing an explanation for the biliary and cutaneous 
manifestations of ulcerative colitis [Das et al, 1990; Das 
et al 1992]. Recently, this protein has been identified to 
be an isoform of tropomyosin [Das et al, 1993]. 
ANCA have been implicated in the pathogenesis of systemic 
vasculitis. However in IBD their pathogenic role is 
unclear. Are ANCA directed solely against neutrophils or 
are they cross-reactive with other cells? 
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6.2 Aims 
The aims of this study were to assess:- 
1.The prevalence rate of Anti-EPI and anti-tropomyosin 
antibody in inflammatory bowel disease. 
2.To assess whether there was any cross-reactivity of Anti- 
EPI antibody or anti-tropomyosin antibodies with ANCA by 
adsorption studies. 
3.To assess any correlation with disease activity or 
treatment of any of these antibodies. 
6.3 Patients and methods 
Sera from the following groups of patients were collected 
and stored at -80°C until studied : 
i)ulcerative colitis, n = 41; median age 37 range 1 8-  6 5  
years. 
ii) patients with ulcerative colitis who had undergone total 
restorative proctocolectomy, n = 30; median age 4 0  range 19 
- 70 years. 6 of these patients had pouchitis at the time 
of sampling. 
iii)Crohn's disease, n = 30, median age 30, range 18- 60 
years. Eleven patients had disease confined to the colon 
and rectum of whom four had had a total proctocolectomy. 
Six had disease confined to the ileum and thirteen had 
disease involving both colon and ileum. 
The diagnosis, in all cases was established by clinical 
criteria, and by histology on biopsies or from gross 
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specimens taken at the time of colectomy. None of the 
patients had any clinical or histological features of a 
systemic vasculitis. 
6.3 1 Controls 
10 patients wi Sera from 34 healthy individuals an 
colonic inflammation due to salmonella (n=2), Campylobacter 
(n=5) and ischaemic colitis (n=3) were used as controls. 
6.32 Disease activity 
The disease activity in patients with Crohn's disease was 
recorded using the Crohn's disease activity index (CDAI) 
[Harvey et al, 19801, and in patients with ulcerative 
colitis the Sutherland score was used [Sutherland et al, 
1987]. 
6.33 Treatment 
Treatment with steroids +/-  aminosalicylates was recorded 
in all cases. 
6.34 ANCA 
ANCA was measure( by indirect immunofluorescence, as 
previously described in chapter 2. The immunofluorescence 
staining pattern was either graded as positive or negative 
in this study. 
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6.35 Antibodies to epithelial cells (ANTI-EPI) 
Epithelial cells of the colon cancer line HT29 were 
cultured in tissue culture flasks with RPMI, 10% foetal 
calf serum, 2.0 mmol/l glutamine, 83 IU/ml of penicillin 
and 83 streptomycin. The cells were then transfered 
to 96 well immunoplates at a concentration of 2 x / 
well, cultured until confluent and fixed with 1% 
formaldehyde for 10 minutes. 
The antibodies to epithelial cells were detected using the 
method as described below:- 
After blocking for 1 hour in 0.1 M phosphate buffered 
saline(PBS)/ 2% bovine serum albumin (BSA) (also used as 
the diluent for subsequent steps) at 37° C, sera from 
patients and controls were added at a dilution of 1/20 and 
incubated for one hour. After washing with PBS-Tween, 
horseradish Peroxidase conjugated sheep antihuman IgG(Fc) 
[British Biotech) was added at a dilution of 1/10,000 
followed by o-phenylenediamine in 0 . 0 5  M citrate buffer 
(2.2 x M final concentration) containing 6 x 10 -3 % 
The reaction was stopped with 20% after 15 minutes and 
the optical density (OD) of the wells read at 492 nm. 
6.36 Antibodies to tropomyosin 
These were detected as previously described [Das et al, 
1993]. Tropomyosin (T-2400, Sigma) was coated onto a 96 
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well Nunc immunoplate at 0.3 per well in 100 of 
carbonate buffer, pH 9.6, overnight at 4°C. Thereafter, 
wells were washed with saline-Tween. Plates were blocked 
with 5% BSA and 1% sheep serum for 1 hour at 37°C. 100 of 
test or control sera diluted 200 fold were added and 
incubated for one hour at 37°C and washed. The conjugate 
sheep alkaline phosphatase antihuman IgG (The Binding Site 
, Birmingham) was added (1/1600) to each well and incubated 
for one hour at 37°C. After washing the subtrate, P- 
nitrophenyl phosphate in 1 mM magnesium chloride, and 50mM 
sodium carbonate, pH 9.8 (Sigma) was added. The plates were 
read at 405nm. 
6.37 Adsorption studies 
Human group O +ve neutrophils were isolated and fixed in 
ethanol onto plates, as previously described [Savage et al, 
1991]. Samples of serum (100 were incubated for 60 min 
with 5 x fixed neutrophils. Supernatants were harvested 
and adsorbed against a second batch of cells. Before use 
for the antibody ELISA, protein concentrations of both the 
pre- and post-adsorption samples were measured by 
spectrophotometry at 260nm and 280nm and adjusted to those 
of the unadsorbed samples. The samples were tested for the 
presence of ANCA by indirect immunofluorescence, as 
described in Chapter 2 to ensure, complete adsorption. 
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6.38 Statistics 
Results are given as the median and range of observations. 
Differences, between the groups of subjects studied were 
analysed by the Kruskal-Wallis analysis of variance and 
differences between pairs of observations by the Wilcoxon 
rank sum test. The Bonferroni correction was used f o r  
multiple comparisons. Correlations were sought using 
Spearman's rank correlation test. 
6.4 Results 
6.41 Disease controls 
Autoantibodies were not detected in any of the disease 
controls. 
6.42 ANCA 
ANCA results are summarized in Table 6.1. Thirty one out 
of 41 patients (76%) with UC had a positive ANCA as did 21 
of 30 patients (70%) with UC who had had a restorative 
proctocolectomy and 13 out of 30 patients (43%) with 
Crohn's colitis. The pattern of ANCA staining was 
perinuclear in all sera. ANCA were not detected in any of 
the healthy or disease controls. 
6.43 Anti-epithelial cell antibodies (Anti-EPI) 
IgG anti-EPI antibody levels also were not normally 
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distributed, and the 95th percentile of 34 healthy control 
sera have been used to define the upper limit of normal. 
The inter-assay and intra-assay coefficients of variation 
for the anti-EPI assay was 9.1 % and 4.2 % respectively. 
Anti-EPI antibody was detected in 20 out of 101 (20%) 
patients (Table 6.1). The distribution of anti-EPI 
antibodies was significantly different between the groups 
studied (p = 0.029), although comparisons between any of 
the patient groups and healthy controls did not show any 
significant differences (Figure 6.1). Anti-EPI antibodies 
were not detected in any of the disease controls. 
6.44 Antibodies to tropomyosin 
The inter-assay and intra-assay coefficients of variation 
for the anti-tropomyosin assay were 9.8 % and 10.2 % 
respectively. 
IgG anti-tropomyosin antibody levels were not normally 
distributed (median OD 0.081, range 0.001-0.774), so the 
95th percentile of 34 healthy control sera was used to 
define the upper limit of normal. Twelve out of 41 
patients (29%) with UC had anti-tropomyosin antibodies, and 
these antibodies were found in three of 30 patients (10%) 
with UC who had had a restorative proctocolectomy, and 
eight out of 30 patients (27%) with Crohn's colitis (Table 
6.1). The distribution of anti-tropomyosin antibodies was 
significantly different between the UC (n=41) and Crohn's 
disease (n=3 O) groups compared to controls, but not between 
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controls and UC patients who had undergone restorative 
proctocolectomy (Figure 6.2). 
Table 6.1 Number of patients with ANCA, AECA, anti-EPI and 
anti-tropomyosin antibodies in the disease study groups. 
6.45 Anti-EPI antibodies, anti-tropomyosin antibodies and ANCA 
Anti-EPI antibodies were significantly higher in patients 
with a positive ANCA (median 0.08 range 0.02-0.57) as 
compared to patients with a negative ANCA (median 0 . 0 6  
range 0-0.23) (p = 0.003). 
Anti-tropomyosin titres were not significantly higher in 
sera with a positive ANCA (median OD = 0.18; range = 0.07 
- 0.47) than in sera with a negative ANCA (median = 0.16; 
range 0.02 - 0.25) (p = 0.11). 
Correlation of the four autoantibodies studied with each 
other is shown in the correlation matrix (Table 6.2). 
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Table 6.2 Correlation matrix of the autoantibodies. 
6.46 Adsorption studies 
The sixty-five ANCA positive sera were incubated with etha- 
nol fixed normal neutrophils. After adsorption with 
neutrophils, ANCA were no longer detectable using an 
indirect immunofluorescence assay. Adsorption of ANCA from 
20 anti-EPI positive sera significantly reduced anti-EPI 
antibodies, from median 0.08 range 0.02 - 0.76 to median 
0.03 range 0.00-0.18, p = 0.001. 
Adsorption of ANCA, from 23 anti-tropomyosin positive sera, 
did not significantly reduce anti-tropomyosin antibodies, 
from median 0.17 range 0.02 - 0.47 to median 0.15 range 
0.01-0.30, p = 0.012. 
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6.47 Disease activity scores and presence of autoantibodies 
The sera were obtained from a wide spectrum of disease 
activity in both ulcerative colitis and Crohn's disease. 
However no significant correlation was found between any of 
the autoantibodies detected with disease activity (Table 
6.3). 
Table 6.3. Correlation of autoantibodies with disease 
activity in UC and Crohn's disease (r-value with corres- 
ponding P value). 
6.48 Treatment 
No significant correlation was found between autoantibody 
titres and treatment with steroids +/-  aminosalicylates 
(Table 6.4). 
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Table 6.4. Correlation of the autoantibodies and treatment 
with steroids +/-aminosalicylates in UC and Crohn‘s disease 
(r-value with corresponding P value). 
6.49 Crohn’s Disease 
Table 6.5 shows the four patients with Crohn’s disease who 
had undergone total proctocolectomy for severe colitis in 
whom the following autoantibodies were found: 
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6.5 Discussion 
The presence of antibodies to colonic epithelium has been 
reported widely by many investigators since the late 1950‘s 
[Broberger et al, 1959; Broberger et al, 1963; Wright et 
al, 1966; Shorter et al, 1970; Chapman et al, 1986; Auer et 
al, 1988], but, more recently a new antibody has been 
described to be an isoform of tropomyosin, which forms part 
of the cytoskeletal protein of cells [Das et al, 1993]. 
Das et al have shown that sera from patients with UC but 
not Crohn’s disease contain antibodies to tropomyosin, 
isolated from the normal colon of patients undergoing 
colectomy for cancer. The tropomyosins are actin binding 
structural proteins found in most cell types. A possible 
explanation for the presence of antibodies, directed 
against several cell types in UC would be that these 
antibodies were directed against different isoforms of 
tropomyosin. 
Data on whether anti-EPI antibodies have any correlation 
with disease activity in ulcerative colitis, or any 
capability for cell cytotoxicity in vitro, have been 
conflicting [Shorter et al, 1970; Das et al, 1990; Snook 
et al, 1991; Auer et al, 1988]. To date, there has been no 
data published on correlation of autoantibodies in 
inflammatory bowel disease with each other, especially with 
ANCA. In addition, the prevalence of anti-tropomyosin 
antibodies to disease activity has not yet been 
demonstrated. 
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The major observations in this study were, to confirm the 
prevalence rate of 20% for anti-EPI antibodies in 
inflammatory bowel disease, with that of both recent and 
older other studies [Wright et al, 1966; Snook et al, 
1991]. However, the prevalence of 29% of antitropomyosin 
antibodies in ulcerative colitis in this series is 
considerably less than the 90% recently reported by Das and 
colleagues. Conversely, the prevalence rate for this 
antibody in Crohn's disease is greater than that reported 
by Das and colleagues. Since there is only one other report 
of the existence of antitropomyosin antibodies, it is 
difficult to comment what the difference in prevalence rate 
is due to. Strong contenders for this difference could be 
methodological or different selection groups. 
There was a significant association between anti-EPI 
antibodies and ANCA. Anti-EPI antibody levels were 
significantly reduced following adsorption of sera by 
neutrophils, suggesting that these antibodies recognised 
antigens also present on neutrophils. This finding is 
promising, since it would enable a more rational 
explanation for the presence of ANCA in UC, where a gross 
vasculitis is seldom demonstrated. 
Finally, there was no significant correlation between the 
levels of anti-EPI antibodies with, either AECA or, anti- 
tropomyosin antibodies, therefore, they are quite distinct 
antibody systems. 
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None of the autoantibodies discussed and investigated, 
including ANCA, AECA, ANTI-EPI and anti-tropomyosin, 
correlate with disease activity. They all persist despite 
total colectomy thus they cannot just be related to colonic 
inflammation. Indeed, patients with colonic inflammation 
due to non-IBD causes such as infective diarrhoeas, do not 
have any evidence of ANCA, AECA or ANTI-EPI antibodies. 
Thus, it can be inferred that, simply removing the colon ie 
the target organ does very little to the actual 
immunological disturbance which gave rise to ulcerative 
colitis. 
Increased prevalence of ANCA and AECA have also been 
reported in pouchitis following restorative 
proctocolectomy. Perhaps the pouchitis is simply a pseudo- 
ulcerative phenomenon, occurring in ileal mucosa which has 
undergone a degree of colonic metaplastic change, and 
villous atrophy, reported to occur in ileoanal pouches with 
time [De Silva et al, 1991; Pemberton, 1993]. This 
hypothesis is further supported by the fact that pouchitis 
responds to treatment using aminosalicylates and steroids 
although metronidazole is undoubtedly, the first line 
agent. Reports have suggested that metronidazole is 
probably exerting an immunosuppressive, rather than an 
antimicrobial role in pouchitis [O'Connell et al, 1986; 
Kmiot et al, 1993]. However stasis in the ileoanal pouch 
and increased proliferation of bacteria, and their 
subsequent sensitivity to metronidazole, is another argument. 
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Overall, ANCA was found more frequently than AECA or anti- 
EPI or antitropomyosin antibodies in IBD. There was a 
higher prevalence of ANCA and AECA in patients with 
ulcerative colitis, as compared with Crohn's disease, and 
yet it is Crohn's disease where vasculitic features have 
been more commonly described. Anti-EPI antibodies were 
slightly more common in Crohn's disease but this was not 
statistically significant. 
My observations show that there is a subgroup of patients 
with ulcerative colitis and Crohns disease who have ANCA, 
AECA, anti-EPI and antitropomyosin antibodies. It is as 
yet, unclear whether these antibodies are of pathogenic 
significance in inflammatory bowel disease but this study 
has made it clear that total colectomy has no influence on 
the prevalence of these autoantibodies. 
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6.6 Summary 
To date, there have been few studies looking simultaneously 
at the prevalence, association with each other, relation to 
disease activity and treatment for the autoantibodies:- 
ANCA, AECA, ANTI-EPI and the recently described antibody to 
tropomyosin. 
The prevalence rates of these autoantibodies were 
determined in patients with ulcerative colitis (UC), n=41; 
UC following restorative proctocolectomy (RPC), n=30 and 
Crohn's disease (CD) n=30 using ELISA. 
A strong association of ANCA with ANTI-EPI (P=0.003) 
antibodies was noted. 
Significant cross-reactivity was noted between ANCA and 
ANTI-EPI antibodies (P=0.001) but not between ANCA and AECA 
(P=0.09) or between ANCA and anti-tropomyosin (P=0.12) by 
removal of ANCA from the sera (adsorption) using isolated 
neutrophils fixed onto microtitre plates. 
The prevalence of these autoantibodies showed no 
correlation with either disease activity or with treatment. 
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A l l  antibodies persisted despite total colectomy, 
indicating that these antibodies do not merely reflect 
colonic inflammation. The cross-reactivity of ANCA with 
ANTI-EPI antibodies may help to explain the high prevalence 
of ANCA in ulcerative colitis. 
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7.1 Introduction 
Leucocytes are prominent in the inflammatory processes 
which occur in chronic inflammatory bowel disease. These 
leucocytes arrive at the site of inflammation from the 
blood stream, by diapedesis through the endothelium. 
Recently, it has been shown that adhesion of leucocytes and 
their transmigration across the endothelium, is dependent 
on cell adhesion molecules (CAMS), which include 
intercellular adhesion molecule 1 (ICAM-1)[Simmons et al,. 
1988], E-Selectin [Polte et al, 1989] and vascular cell 
adhesion molecule 1 (VCAM-1) [Bevilacqua et al, 1989]. 
ICAM-1 and VCAM-1, belong to the immunoglobulin supergene 
family and bind respectively to the ß2 integrins (LFA1 and 
MAC1) [Marlin et al, 1987; Diamond et al, 1991] on 
lymphocytes, granulocytes, monocytes and to the B1 integrin 
(VLA4) [Hemler et al, 1987] on lymphocyes, eosinophils, 
basophils and monocytes. 
ICAM-1 is found on many cell types, whilst VCAM1 is found 
mainly on endothelial cells, follicular dendritic cells, 
neural cells and glomerular parietal epithelium [Garner et 
al, 1993]. 
E-Selectin is found only on activated endothelium and binds 
to granulocytes, monocytes and some memory T-cells (CLA+) 
[Shimizu et al, 1991; Picker et al, 1991]. Raised levels of 
soluble forms of these intercellular cell adhesion 
molecules :- SICAM-1, SE-Selectin and sVCAM-1 have been 
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found in the plasma of a variety of disease states, 
including chronic inflammatory liver disease [Adams et al, 
1992a], diabetes [Ballantyne et al, 1991], some carcinomas 
[Adams et al, 1992b], allograft rejection [Gearing et al, 
1992; Harning et al, 1991] and systemic vasculitides 
[Hauschild et al, 1992]. 
7.2 Aims 
The aims of this study were to determine levels of the 
soluble CAMS, in patients with chronic inflammatory bowel 
disease, in relation to prevalence, treatment and disease 
activity. 
7.3 Patients and methods 
Plasma from 115 patients with chronic inflammatory bowel 
disease, and 24 healthy controls were collected and stored 
at -80° C. The diagnosis of inflammatory bowel disease in 
the study group had been made by prior clinical, 
radiological, endoscopic and histopathological methods. 
7.3 1 Ulcerative colitis 
Sera were obtained from 81 patients with ulcerative 
colitis, median age 39, range 18-70 years of whom 39 were 
males. These patients were placed in two groups depending 
on whether they had UC (n=49) or whether, they had UC and 
had undergone restorative proctocolectomy (n=32). 
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From the RPC group, 8 patients had clinical pouchitis at 
the time of investigation. In addition, two patients had 
undergone prior liver transplantation for sclerosing 
cholangitis. 
7.32 Crohn's Disease 
There were 34 patients with Crohn's disease, median age 30, 
range 18-60 of whom 18 were males. 10 patients had disease 
confined to the colon and rectum, 10 patients had disease 
confined to the small bowel alone, and 14 had disease 
affecting the large and small bowel. 4 of the above Crohn's 
patients had an ileostomy after undergoing proctocolectomy. 
Active IBD was defined by the presence of symtoms such as 
diarrhoea, rectal bleeding, constipation, abdominal pain, 
fever and weight loss; together with endoscopic and 
histological evidence of mucosal inflammation. 
Inactive disease was defined by the absence of symptoms and 
endoscopic normal mucosal appearances. Treatment with non- 
steroidal anti-inflammatory drugs, steroids or both was 
undertaken in all the active disease study groups. 
Assessment of the disease activity, by measurement of 
haemoglobin, platelet count, albumin and C-reactive 
protein, was recorded in all patients. 
The control group consisted of plasma taken from 24 healthy 
individuals whose median age was 34 years, range 21-41 
years. 
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7.33 SICAM-1 and sE-Selectin ELISA 
The levels of SICAM-1 and sE-selectin were measured by 
commercially available two site ELISA (British 
Biotechnology Products (BBP)). Sequential incubations were 
performed in microtitre plates as follows, the plates were 
washed three times between each incubation, with wash 
buffer: (a) anti-human ICAM-1 or E-Selectin monoclonal 
antibody; (b) plasma samples diluted 1 in 10 for SICAM-1 
assay and 1 in 5 for sE-selectin assay, standard 
concentrations of SICAM-1 (3.25-52 ng/ml) or of sE-selectin 
(1.875-30 ng/ml) (respectively) and biotinylated anti-human 
ICAM-1 or E-selectin (respectively) monoclonal antibody, 
incubated for 2 hours at room temperature; (c) 
streptavidin-horseradish Peroxidase (HRP) anti-human IgG 
conjugate, incubated for 1 hour at room temperature and (d) 
tetramethylbenzidine Substrate. The optical density was 
read after 10 minutes at 450 nm. The SICAM-1 and sE- 
selectin concentrations in the test plasma, were determined 
from the standard curve. 
7.34 sVCAM-1 ELISA 
The levels of sVCAM-1 were measured by a two site ELISA. 
Microtitre plates were coated with mouse anti-human VCAM-1 
monoclonal antibody (The Binding Site, Birmingham), at 2.5 
in 0.05M bicarbonate buffer pH 9.6, for 16 hours at 
4°C. The plates were blocked with 1% bovine serum albumin 
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(BSA) in 0.1M phosphate buffered saline (PBS) /O. 05% Tween 
20 pH 7.4. Sequential incubations of the following were 
made for 1 hour at 37°C, and the plates were washed between 
incubations with PBS/Tween: (a) Plasma samples diluted 1 in 
10 in 0.1M PBS/0.05% Tween 20 pH 7.4; (b) goat polyclonal 
anti-human VCAM-1 (British Biotech) diluted 1 in 2000 in 
0.1M PBS/0.05% Tween 20 pH 7.4, which had been incubated 
with 2% normal mouse serum (NMS) for 1 hour at 37°C; (c) 
HRP conjugated donkey anti-goat IgG (Fc) (The Binding Site) 
diluted 1 in 20000 in 0.1M PBS/0.05% Tween 20 pH 7.4, which 
had been incubated with 2% NMS for 1 hour at 37°C prior to 
use; (d) o-phenylenediamine Substrate in 0.05M citrate 
phosphate buffer pH 5. The reaction was stopped with 20% 
sulphuric acid after 15 minutes and the OD read at 492 nm. 
7.35 C-reactive protein and a-1 glycoprotein 
Serum levels of C-reactive protein (CRP) and of a-1 
glycoprotein were measured by latex immunoturbidometric 
assay. 
7.36 Statistics 
The data were not normally distributed and therefore, are 
expressed as medians with interquartile ranges. Differences 
in adhesion molecule distributions between the patient 
groups were analysed by the Kruskal-Wallis one way analysis 
of variance. The significance of the differences between 
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patients and controls were determined by the Wilcoxon rank 
sum test, and P values adjusted by the Bonferroni method 
for multiple comparisons. The Spearman rank correlation 
coefficient test was used to determine associations. The 5% 
level was used to indicate statistical significance. 
7.4 Results 
7.41 Plasma ICAM-1 
The median(ng/ml) and range of SICAM-1 was 250(140-670) for 
UC, 290(140-510) for RPC and 280(90-630) for CD. These 
values were significantly different from those obtained 
from the 24 healthy controls 125 (10-250) . Subgroup analysis 
in relation to disease activity revealed significant 
differences between active and inactive disease states in 
UC (P=0.031), RPC (pouchitis regarded as active disease in 
this group) (P=0.0004), and CD (P=0.045)(Figure 7.1 and 
Table 7.1). 
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Table 7.1. Medians with ranges of soluble CAMS in relation 
to disease activity. 
There was no correlation found between levels of SICAM-1 
and treatment with steroids and/or non-steroidal anti- 
inflammmatory drugs using analysis of variance (F=1.16, 
P=0.33). Significant correlation was found between the 
levels of a-1 glycoprotein, but not CRP with ICAM-1 (Table 
7.2). 
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Table 7.2 Spearman correlation matrix for soluble CAMS, C- 
reactive protein and al-glycoprotein. 
7.42 Plasma E-Selectin 
The median(ng/ml) and range of distribution of SE-Selectin 
was 55(20-140) for UC, 53(20-135) for RPC and 60(25-115) 
for CD. These values were significantly greater than those 
obtained from the controls 25(5-105). Subgroup analysis in 
relation to disease activity revealed significant 
differences between active and inactive disease states in 
UC (P=0.0025), RPC (P=0.0012) and CD (P=0.0199)(Figure 7.2 
and Table 7.1). There was no correlation found between 
levels of SE-Selectin and treatment with steroids or non- 
steroidal anti-inflammatory drugs using analysis of 
variance (F=0.62, P=0.61). Significant correlation was 
found between the levels of CRP but not a-1 glycoprotein 
with SE-Selectin (Table 7.2). The highest values of sICAM1 
(630 ng/ml) and SE-Selectin (180 ng/ml) were seen in a 
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patient who had undergone restorative proctocolectomy 
during an acute episode of pouchitis. 
7.43 Plasma VCAM-1 
The median optical density (OD) and range of distribution 
of sVCAM-1 was 1.354 (0.676-1.845) for UC, 1.279 (0.737- 
2.023) for RPC and 1.073 (0.663-1.859) for Crohn's disease. 
These values were not significantly greater than those 
obtained from the controls 1.073 (0.663-1.859). Subgroup 
analysis in relation to disease activity revealed no 
significant differences between active and inactive disease 
states in UC (P=0.100), RPC (P=0.296) and Crohn's disease 
(P=0.569)(Figure 7.3 and Table 7.1). 
No significant correlation was found between the levels of 
both C-reactive protein and a-1 glycoprotein with sV-CAM1 
(Table 7.2). 
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7.5 Discussion 
Leucocyte migration is a tightly regulated process, 
involving CAMs expressed on endothelial cells as well as 
leucocytes. Circulating adhesion molecules appear to arise 
from proteolytic cleavage of the extracellular domain of 
adhesion molecules [Adu et al, 1994; Rothelin et al, 1991]. 
Increased cell surface expression of these adhesion 
molecules is regulated by cytokines such as IL-1, TNF and 
yinterferon [Kishimoto et al, 1989; Keelan et al, 1992]. 
It seems likely that the expression of these CAMs would be 
increased on endothelium in the vicinity of tissue 
inflammation and this would in turn lead to an increase in 
plasma levels of soluble CAMS. It is also possible that 
soluble CAMs compete for inflammatory cell binding and 
thus, may act in a negative feedback manner limiting, 
rather than promoting cell adhesion [Barrett et al, 1993]. 
This study demonstrates that circulating soluble adhesion 
molecules sICAM1 and SE-Selectin are detectable in greater 
amounts in the plasma of patients with chronic inflammatory 
bowel disease, as compared with healthy controls. Since 
ICAM-1 is found on many cell types as well as on 
endothelium, the raised circulating levels could reflect 
lymphocyte activation and non endothelial tissue injury, as 
well as endothelial injury. 
Another interesting possibility comes from the discovery 
that ICAM-1 is the major cell surface receptor for 90% of 
human rhinovruses. The gene for this receptor maps to 
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chromosome 19 which also contains the gene for other 
picornavirus receptors. Increased expression of SICAM-1 has 
been shown to inhibit rhinovirus infection of cells from 
the upper respiratory tract [Marlin et al, 1990]. It seems 
conceivable that ICAM-1 may play an antiviral role in the 
vicinity of bowel mucosa. 
Vasculitis has previously been described in IBD [Murch et 
al, 1992; Wakefield et al, 1991] however, the mechanisms 
involved are poorly understood. E-selectin is found only on 
activated endothelium and elevated levels provide further 
proof that there is endothelial activation in chronic IBD. 
Recent evidence using immunoelectron microscopy has shown 
ultrastructural evidence that E-Selectin is a secretory 
product of endothelial cells in IBD, released via 
exocytosis [Ohtani et al, 1992]. 
Binding of soluble CAMS to their target cells may also 
deliver an activating stimulus. Recombinant sE-Selectin has 
been shown to be a powerful neutrophil chemoattractant, and 
to activate the integrin CR3 [Lo et al, 1991]. 
This study has shown increased levels of SICAM-1 and sE- 
Selectin in both active inflammatory bowel disease and 
pouchitis. Recently increased pro-inflammatory cytokine 
expession has also been reported [Gionchetti et al, 1993]. 
It is well known that in the ileoanal pouch colonic 
metaplasia and villous atrophy occur. Similar expression of 
adhesion molecules and cytokine expression in pouchitis and 
active UC suggest perhaps that pouchitis represents a 
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reactivation of the immunological mechanisms which brought 
about UC. 
In this study levels of sVCAM1 did not differ significantly 
in chronic IBD from healthy controls. Immunohistochemical 
localization studies on frozen tissue sections have also 
reported similar findings [Dean et al, 1993]. This may 
possibly be due to the restricted expression of this 
molecule on certain cell types which, perhaps are not 
actively involved in the inflammatory processes in chronic 
IBD. 
This study suggests that SICAM-1 and SE-Selectin levels are 
increased during active IBD and pouchitis, and that the 
measurement of circulating levels of these molecules may be 
used as sensitive markers of ongoing inflammation. 
Inhibition of these leucocyte-endothelial cell interactions 
may bring about decreased leucocyte transmigration to the 
site of inflammation, and hypothetically may provide a new 
target for the control of IBD. 
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7.6 Summary 
Levels of SICAM-1, SE-Selectin and sVCAM-1 might reflect 
endothelial activation and injury, and could be useful 
markers of disease activity in IBD. 
The aims of this study were to determine levels of the 
soluble forms of ICAM-1, E-Selectin and VCAM-1, in relation 
to prevalence, treatment and disease activity in IBD. 
Plasma was obtained from the following patients:- UC 
(n=49); UC who had undergone RPC [n=32 (8 of whom had a 
clinical pouchitis)], Crohn's disease (n=34) and 24 healthy 
controls. 
Plasma SICAM-1 levels [median with ranges (ng/ml)] were 
significantly higher in patients with active UC [270 (90- 
510) ], pouchitis [415 (310-670) ], and active Crohn's [305 
(200-630)] compared to inactive UC [225 (140- 
425) (P=0.031) ], non-inflamed ileoanal pouch [260 (140- 
380) (P=0.0004) ] and inactive Crohn's [245 (90- 
520) (P=0. 045) ] respectively and controls. SE-Selectin 
levels were also significantly higher in patients with 
active UC [55 (40-140)], pouchitis [90 (45-145)], and 
active Crohn's [78 (30-115)] compared to inactive UC [45 
(20-80)(P=0.003)], non-inflamed ileoanal pouch [45(20- 
90) (P=0.001) ] and inactive Crohn’s [48 (25-90) (P=0.020) ] 
respectively and controls. 
Increased levels of SICAM-1 and SE-Selectin occur during 
active IBD and pouchitis, which may be used as sensitive 
markers of ongoing inflammation. 
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8.1 Introduction 
The activation of the immune system in IBD affects all cell 
systems associated with the mucosal immune system. 
Cytokines are important in orchestrating the interactions 
of cells involved in immunological and inflammatory 
reactions. Cytokines are multifunctional peptides, and the 
functions of the pro-inflammatory cytokines in relation to 
IBD are given in Chapter1. 
In this chapter, studies of the local mucosal levels and 
plasma levels of IL-8, TNFa, IL-1ß and IL-6 are 
individually shown, following a brief introduction to 
provide clarity. 
8.2 Aims 
The aims of this study were to investigate the role of the 
pro-inflammatory cytokines:- IL-8, TNFa, IL-1ß and IL-6 in 
inflammatory bowel disease. 
Plasma levels of these cytokines were determined at the 
same time as trying to establish the local production in 
the mucosa at different anatomical sites some of which 
were/were not involved by chronic inflammation by means of 
tissue biopsies. 
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8.3 Patients and methods 
8.31 Plasma samples 
Plasma samples were taken in heparinised tubes, spun down 
and stored in endotoxin free tubes. 
Table 8.1 Number of patients in disease categories:- 
8.32 Disease activity and treatment 
The disease activity was assessed in UC and Crohn's, using 
a simple score as previously described [Kodner et al, 1990] 
and the Crohn's disease activity index [Best et al, 1976] 
respectively. 4 out of 9 patients with Crohn's colitis also 
had evidence of ileal Crohn's disease. 
Treatment with aminosalicylates +/-  steroids was recorded 
in all patients including details of local steroid therapy 
using enemas. 
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8.33 Mucosal biopsies 
Control healthy mucosal biopsies were obtained from 
patients undergoing colectomy for non-IBD disorders such as 
colon cancer and slow transit bowel disorders with a 
histologically normal colon and terminal ileum. 
The mucosal biopsies were taken simultaneously with plasma 
samples in the operating theatre, immediately after 
colectomy together with an ileal biopsy if this was 
available or at the time of colonoscopy. Biopsies were 
taken from:- 
1. rectosigmoid colon between 20 and 60cm 
2. ileum (when available). 
The biopsies were placed immediately in cool Hanks buffered 
saline (Hanks) supplemented with glutamine, penicillin, 
streptomycin (GPS) and 10% foetal calf serum (FCS). The 
biopsies were minced using 23 gauge needles and a 
microscope as shown in Figure 8.1, and washed. (Each 
washing step consisted of spinning the cells in a 
centrifuge at 1600 RPM for 5 minutes followed by the 
removal of the supernatant and the addition of fresh 
culture medium. 0.75 mM EDTA in Hanks/GPS/FCS was used to 
lyse the epithelial cells, followed by washing. 1 mM 
dithiothrietol in Hanks/GPS/FCS was used to remove surface 
mucous and washed. 
Next, the tissue matrix was subjected to enzymatic 
dispersion at 37°C with collagenase (Sigma) at conc O.  5mg/ml 
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and hyaluronidase (Sigma), at conc 1 mg/ml in RPMI/GPS/FCS, 
for 4 hours, with pipetting every 20- 30  minutes. After 
filtering with a stainless steel filter the cells were 
resuspended in RPMI/GPS/FCS, and mononuclear cells further 
separated using a Percoll gradient followed by counting in 
an improved Neubauer chamber. 
Identity and viability 
Identity of the mononuclear cells was assessed by flow 
cytometry (Department of Immunology, University of 
Birmingham) and viability using Trypan blue 1:1, if >95%, 
further experimentation was performed. 
The cells were suspended in RPMI/GPS/FCS, and incubated in 
Nunc cell culture plates for 48 hours with nothing or with 
1 of E. Coli lipopolysaccharide (Sigma) (control) , at 
a concentration of 2 x at 37°C, in a 5% CO, chamber. 
The mononuclear cells were quantitated at the end of the 
culture period, and cytokine release corrected for the 
number of cells alive and viable. 
Maximal secretion of the cytokine by E.Coli LPS (Sigma) was 
performed, to elucidate the optimal concentration of LPS 
required to produce maximal cytokine production by the 
isolated mononuclear cells. Biopsies were taken from 5 
healthy patients, and cytokine secretion assessed using LPS 
at concentrations of 0.001, 0.01, 0.1, 1.0, and 10 
micrograms/ml (Appendix 2 ) .  Potency of the LPS used in 
these studies was confirmed by experiments on mononuclear 
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cells isolated from healthy mucosa (Appendix 2). 
E Coli LPS (1.0 was also used to assess cytokine 
production in both healthy and inflamed colon biopsies. 
Both the plasma and the supernatants were stored at -80 °C 
in endotoxin free (Falcon) tubes. The mononuclear cells 
were quantitated at the end of the culture period and 
cytokine release corrected for the number of cells alive 
and viable. 
Levels of serum C-reactive protein (CRP) and al-acid 
glycoprotein were also measured by latex 
immunoturbidometric assay. 
8.34 Cytokine Elisa 
Monoclonal antibody for TNFa (British Biotechnology, UK), 
IL-1ß (Janssen, Belgium), IL-6 (Monosan, Belgium) and IL-8 
(British Biotechnology) were individually coated overnight, 
in coating buffer (pH 9.6) (Appendix 2 ) ,  onto Nunc 96 well 
plates, at a concentration of 10 except for IL-8 
which was coated at 2.5 After washing with 
PBS-Tween, which was used for all steps of washing, the 
plates were blocked for one hour with 1% BSA PBS-Tween at 
37°C. After washing, 100 of standard or test sample 
(supernatant or plasma) was incubated for one hour at 37°C. 
After washing, alkaline phosphatase conjugated polyclonal 
antibody (British Biotechnology) to the specific cytokine 
was incubated for one hour at 37 °C. The Substrate, 
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orthophenylene diamine, was then added after further 
washing, and 20% was added, after 15 mins, to stop the 
reaction. The optical density of the plate was then read at 
4 9 2  nm, these steps are summarized in Figure 8.2. 
Results were plotted against a standard curve (Figure 8.3) 
for each cytokine. High values of test samples were 
determined by serial dilutions. These assay systems had 
previously been validated by the Department of Infection, 
University of Birmingham and were regularly performed in 
the Department of Renal Medicine, Queen Elizabeth Hospital. 
The same methods described above were used to measure local 
mucosal production of TNFa, IL-1ß AND IL-6 in the 
supernatants. I had also previously carried out cytokine 
ELISAs on plasma of septic patients [Patel et al, 1994b; 
Helle et al, 1990]. 
8.35 Statistical analysis 
Results were not normally distributed, and therefore have 
been expressed as medians with ranges. The Mann-Whitney U 
test has been employed to show differences between the 
various groups and Wilcoxon rank sum test for comparing 
paired data. Analysis of variance was carried out using the 
general linear model. 
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8.4 Interleukin 8 
8.41 Introduction 
Neutrophil accumulation in the inflamed intestinal mucosa 
is a prominent feature in ulcerative colitis. The granules 
of neutrophil granulocytes contain a number of enzymes, for 
example myeloperoxidase and lactoferrin, which are 
important in the combat against bacteria [Klebanoff, 1975]. 
These granule enzymes, some of which are proteolytic, can 
be released upon stimulation, together with cytotoxic 
oxygen metabolites [Weissmann et al, 1980]. Therefore, 
activated neutrophils may contribute to tissue damage at 
sites of inflammation. The factor(s) responsible for the 
mucosal recruitment of neutrophils in ulcerative colitis 
are not certain. Human neutrophil activating peptide 
(NAPl)/interleukin-8 is a single non-glycosylated peptide 
chain, its main activities include activation and 
chemoattraction of neutrophils [Peveri et al, 1988; Thelen 
et al 1988; Lindley et al, 1988]. It was originally 
isolated from endotoxin treated monocytes but can also be 
produced by a variety of other cells upon stimulation with 
a number of cytokines including IL-1 and TNFa [Striter et 
al, 1988; Striter et al, 1989, Watson et al, 1988]. 
Aims, patients and methods 
As described earlier. 
1 6 6  
8.42 Results (IL-8) 
There was no significant difference in the values of plasma 
IL- 8 in the study groups compared with controls (Figure 
8 . 4 )  . 
However, there were significant differences in IL- 8 
production by lamina propria mononuclear cells, in vitro, 
from the colonic and ileal biopsies in the disease study 
groups when compared with healthy controls as shown in 
Figure 8 .5  and 8 . 6  respectively. 
Significantly higher values of IL-8 were recorded, from 
rectosigmoid biopsies, in patients with active UC and 
Crohn's colitis, then from those with inactive UC and 
healthy controls (P < 0.001) {Figure 8 .5 ) .  
Out of the 15 patients with active UC, 9 who were receiving 
steroid enemas, had significantly lower IL- 8 levels 
recorded median (range; pg/ml) 480 (280- 910)  , than those 
who didn't 640  ( 5 0 0- 1 3 0 0 ) .  
The distribution of IL- 8 in the ileal biopsies revealed no 
significant differences between active and inactive UC with 
healthy controls but significantly higher values of IL- 8 
were demonstrated between Crohn's ileum and healthy 
controls (Figure 8 . 6 ) .  
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Table 8.2 P-values comparing IL-8 levels in inflammatory 
bowel disease with healthy controls (P<0.05*). 
Analysis of variance did not reveal any significant 
difference from the use of systemic steroids and IL-8 
production from isolated mucosal mononuclear cells 
(F=0.79, P>0.10). 
Stimulation of isolated rectosigmoid mononuclear cells by 
1.0 of E. Coli LPS (Sigma) revealed increased 
production of IL-8 from [median, range, pg/ml]:- 670 (250- 
1340) to 710 (200-1200) in inflamed UC colon; and increased 
production in healthy colon from 30(20-70) to 40(20-100). 
This difference was statistically significant in the two 
groups (P<0.05) . 
The intra-assay and inter-assay coefficients of variation 
for the IL-8 ELISA assay were 7.5% and 9.1% respectively. 
Preliminary studies showed that the amount of IL-8 produced 
by mononuclear cells isolated from inflamed rectosigmoid 
mucosa in IBD was usually in the range detected by the 
assay. 
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8.43 Discussion IL-8 
These results show that the degree of disease activity was 
proportional to the levels of IL-8 measured from the 
colonic biopsies but not from the plasma or ileal biopsies 
in UC. 
Recent studies have also reported that plasma IL-8 levels 
do not reflect the local disease activity in IBD [Raab et 
al, 1993]. Increased IL-8 production locally in the 
inflamed colonic mucosa in active UC and Crohn's colitis 
may provide an explanation for the early recruitment of 
neutrophils and their subsequent activation [Raab et al, 
1993]. 
Bacterial LPS, immune complexes and several cytokines 
including IL-2, IL-3, TNFa , GM-CSF and IL-1 are strong 
inducers to IL-8 production in mononuclear phagocytes 
[Baggiolini et al, 1989; Striter et al, 1988; Striter et 
al, 1989; Watson et al, 1988]. It is highly likely that IL- 
8 is a principal mediator of inflammation in ulcerative 
colitis, although many other cytokines are now being 
implicated. 
Possible steps leading to colonic inflammation can be 
illustrated thus:- 
Autoimmune stimulus for UC 
Macrophages and T-cell activation 
Increased IL-8 production 
Neutrophils 
Tissue inflammation 
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The mechanisms recruiting and activating mononuclear cells 
and macrophages in the intestinal mucosa are probably 
multifactorial. The cellular source of IL-8 in inflamed 
mucosa has been shown to be from macrophages, T cells and 
also from neutrophils to a lesser extent. Intradermal IL-8 
has been shown in animals to cause plasma exudation and 
massive neutrophil infiltration [Colditz et al, 1989]. It 
also causes these cells to degranulate and exhibit a 
respiratory burst. 
IL-8 probably plays an important role in neutrophil 
diapedesis through vascular endothelium and the focal 
recruitment of neutrophils at inflamed sites [Peveri et al, 
1988; Thelen et al, 1988; Lindley et al, 1988, Van Damme et 
aï, 1988, Baggiolini et al, 1989]. 
Adhesion molecules also play a significant role in the 
trasmigration of neutrophils across vascular endothelium as 
discussed in Chapter 7. 
Considering the part IL-8 plays in the disease process it 
may be possible to control tissue damage and inflammation 
that occurs in UC and Crohn's by controlling levels of IL-8 
locally. 
2 possible methods are:- 
i.Steroids (used currently) 
ii.Anti-interleukin-8 therapy 
Steroids 
In this study, treatment with systemic steroids had little 
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significance on cytokine production in vitro. However in 
those patients who received steroid enemas in addition had 
lesser degree of inflammation in the rectosigmoid region 
and significantly lower production of IL-8 by isolated 
MNCs. 
But I noted that the inflammation was reduced only in the 
rectosigmoid region on opening the colectomy specimens and 
not along the whole length of the colon. Perhaps, in time, 
a method of local application of steroids, along the whole 
length of the colon might become feasible but this cannot 
be the answer in the long term as steroid therapy is 
fraught with disadvantages. 
Anti-IL-8 therapy 
Recent technology has made possible the production of anti- 
IL-8 antibodies. The advantages of the use of anti-IL-8 is 
that it is specific and thus could effectively block the 
cascade process illustrated. Several disadvantages are 
apparent:- 
i) UC and Crohn's are chronic diseases, and therefore 
multiple doses of anti-IL-8 would have to be administered. 
ii) Anti-IL-8 is expensive to manufacture at present 
iii) Generalised side effects eg, fever, rashes, metabolic 
disturbances and sweating are likely (these side effects I 
witnessed first hand, when administering anti-TNF 
monoclonal antibody to patients with severe sepsis). 
iv) Long term safety and efficacy of anti-IL-8 have yet to 
be established. 
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8.5 TNFa 
8.51 Introduction 
Tumour necrosis factor a (TNFa) /cachectin is a cytokine 
produced mainly by activated macrophages and monocytes. In 
the last 4 years there has been immense interest in TNF, 
both as a mediator of tissue maturation and local immunity, 
and as a destructive agent capable of causing profound 
cachexia and tissue injury. The balance of beneficial and 
deleterious effects are determined by its level of 
production and its interaction with other mediators [Tracey 
et al, 1988; Beutler et al, 1988; Ziegler, 1988; Tracey et 
al, 1989]. 
TNFa is produced in response to inflammation and sepsis. In 
addition to its role in the elimination of pathogens, TNFa 
induces necrosis of certain types of tumour in vivo 
[Carswell et al, 1975] and is cytotoxic for many 
transformed cell lines in vitro [Tracey et al, 1989]. 
However, high levels of TNFa in vivo can be detrimental 
since they induce metabolic acidosis, wasting, and 
suppression of haematopoiesis. Abnormal expression of this 
pleiotropic molecule leads to many of the systemic 
manifestations of chronic disease. These include cachexia 
[Beutler et al, 1988], suppression of haemopoeitic colony 
formation and increased red blood cell destruction leading 
to anaemia [Tracey et al, 1988], and acts as an endogenous 
pyrogen [Dinarello et al, 1986]. 
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The local and systemic effects of the inflammatory bowel 
diseases together with the observation that the intestinal 
tract contains receptors for TNFa [Beutler et al, 1985] 
suggests that TNF may be involved in many of these effects. 
Aims, patients and methods 
As described earlier. 
8.52 Results 
The distribution of TNFa in the plasma, rectosigmoid colon 
and ileum is shown in Figures 8.7 - 8.9 respectively. 
There was no significant difference noted in the values of 
plasma TNFa in the study groups compared with controls 
(Figure 8.7) in UC but slightly higher levels of TNF were 
noted in patients with Crohn's. 
However, there were significant differences in the TNFa 
production by lamina propria mononuclear cells from colon 
in patients with active UC and Crohn's colitis when 
compared with healthy controls (P < 0.001)(Figure 8.8). 
Out of the 15 patients with active UC, 9 who were receiving 
steroid enemas had significantly lower TNFa levels recorded 
median (range; pg/ml) 90 (0-440), than those six who didn't 
190 (50-710). 
The distribution of TNFa in the ileal biopsies revealed no 
significant differences between active and inactive UC with 
healthy controls but significantly higher values of TNFa 
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were demonstrated between Crohn's ileum and healthy 
controls (Figure 8.9). Increased TNFa levels were 
demonstrated, from MNCs isolated from ileum, in patients 
with Crohn's disease, which was reported as histologically 
normal. 
Table 8.3. P-values comparing TNFa levels in inflammatory 
bowel disease with healthy controls (p<0.05*). 
Analysis of variance did not reveal any significant 
difference from the use of systemic steroids and TNFa 
production from isolated mucosal mononuclear cells (F=0.32, 
P>0.10) . 
Stimulation of isolated rectosigmoid mononuclear cells by 
1.0 of E Coli LPS (Sigma) revealed increased 
production of TNFa from [median, range, pg/ml] :- 100 ( 0 -  
710) to 120 (0-600) in inflamed UC colon; and increased 
production in healthy colon from 0(0-40) to 20(0-50). This 
difference was statistically significant in the two groups 
(P<0.05). The intra-assay and inter-assay coefficients of 
variation for the TNF ELISA assay were 6.7% and 11.2% 
respectively. Preliminary studies showed that the amount of 
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TNFa produced by mononuclear cells isolated from inflamed 
rectosigmoid mucosa in IBD was usually in the range 
detected by the assay. 
8.53 Discussion [TNF] 
TNFa production is increased in the mucosa of patients with 
active UC and Crohn's colitis compared with controls. 
Possible reasons for this are that this is directly 
proportional to the degree of colonic inflammation from 
where the biopsies were taken. On the other hand, if this 
was simply the case, why then was increased TNFa expressed 
in Crohn's ileum which was histologically normal? 
As is well known, at present, there is no satisfactory 
animal model of IBD and particularly it is worth noting 
that TNFa has not been found to be increased in 
experimental models (1-chloro-2,4-dinitrobenzene {DNCB}) of 
colitis in rabbits, compared to controls [Mack et al, 
1992]. 
The mononuclear cells from mucosal biopsies taken from 
patients with Crohn's disease, secreted relatively more 
TNFa compared to active UC. This cannot simply be explained 
on the degree of colonic inflammation. TNFa production in 
Crohn's disease has been linked to the production of 
granulomas and this may have some bearing on the difference 
seen. 
As with IL-8, these results looking at TNFa also did not 
181 
correlate with systemic steroid therapy. Again, this can be 
explained by the fact that the mucosal biopsies taken from 
areas of severe inflammation had mononuclear cells which 
are already activated and these cells are unresponsive or 
refractory to steroid therapy. 
It is quite evident from the numerous reports in the 
literature that it is a multifunctional cytokine [Beutler 
et al, 1987]. TNFa infused systemically into rats causes 
intestinal haemorrhage and necrosis [Sun et al, 1988]. This 
is due to breakdown in the intestinal vascular network 
caused by TNF-induced pro-coagulant activity of the 
endothelial cells and increased neutrophil adherence and 
mediator release [Cerami et al, 1988]. TNFa is also 
angiogenic and may help in the healing of diseased mucosa 
[Schroder et al, 1987]. TNFa has also been shown to be 
important in the granulomatous response to mycobacteria in 
mice [Kindler et al, 1989]. 
A macrophage influx is a feature of both ulcerative colitis 
and Crohn's disease. However, it is still unknown why 
granulomas are seen only in Crohn's disease. 
TNF also has cachectic activity [Oliff et al, 1987] and may 
contribute to the weight loss frequently seen in children 
with IBD (as do other factors such as malnutrition). 
Raised plasma CRP levels are also associated with IBD. 
Infusion of graded doses of TNFa into patients leads to a 
dose dependant increase in plasma CRP levels [Michie et al, 
1988]. 
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The finding of increased TNFa in colonic mucosa in active 
IBD supports the idea that TNFa is one possible mediator of 
enhanced IL-8 synthesis in inflamed mucosa. 
Attempts by some investigators [Macdonald et al, 1990] to 
identify the mucosal cell type secreting the TNFa have been 
equivocal. It is likely that more than one particular cell 
population is responsible for TNFa release and also that 
numerous other mediators are also released simultaneously 
in the inflamed mucosa. 
In recent years there has been much interest in TNF being 
a major mediator in the inflammatory processes related to 
sepsis, other inflammatory diseases, neoplastic diseases 
and autoimmune diseases. Indeed animal and human studies 
have reported clinical benefit in the use of anti-TNFa 
monoclonal therapy in severe sepsis [Tracey et al, 1987; 
Hinshaw et al, 1990]. Recently, I have participated in a 
large, prospective, multicentre, multinational trial on the 
efficacy of murine monoclonal antibody to tumour necrosis 
factor in severe sepsis. Outcome in the study was assessed 
as survival to 28 days. Results have not been finalised but 
the interim analysis is encouraging. A definite improvement 
in mortality by 9% has been found when given to patients 
with septic shock , compared to placebo. In chronic IBD the 
role of anti-TNFa still needs further study. 
It is also unlikely that TNFa production is specific for 
IBD and that as more enteropathies are studied TNFa 
production may be a common feature. 
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8.6 Interleukin 1ß 
8.61 Introduction 
Interleukin 1 (IL-1) is a polypeptide produced, 
predominantly, by stimulated macrophages and monocytes. Two 
structurally distinct forms of IL-1, IL-a and IL-1ß have 
been identified. They are coded by two separate genes on 
chromosome 2 and messenger RNA for IL-1ß predominates over 
that coding for IL-a [Dinarello, 1988]. 
Although they share only 26% sequence homology, their 
biological activities are, for the most part, identical 
[Enders et al, 1987]. This could be explained by identical 
cell surface receptors for the two forms of IL-1 [Dower et 
al, 1986]. 
Interleukin 1 exerts an influence over a wide range of 
biological functions. It acts as an endogenous pyrogen and 
induces hepatocytes to synthesize acute phase proteins - 
for example serum amyloid A, C-reactive protein and 
fibrinogen [Dinarello, 1988; Enders et al, 1987; Dinarello, 
1984]. 
It activates T-lymphocytes [Mizel, 1982], increases 
antibody synthesis by B-cells [Falkoff et al, 1983] and 
induces granulocyte release from the bone marrow 
[Kampschmidt, 1981]. It enhances fibroblast collagen 
production [Schmidt et al, 1982] and alters prostaglandin 
production. 
Information, at present, on IL-1ß production in UC and 
18 4 
Crohn’s disease is sparse. 
Aims, patients and methods 
As described earlier. 
8.62 Results 
The distribution of IL-1ß in the plasma, rectosigmoid colon 
and ileum is shown in Figures 8.10, 8.11 and 8.12 
respectively. 
There was no significant difference in plasma IL-1ß values 
between the study groups, Figure 8.10. 
Preliminary studies showed that the amount of IL-10 
produced by mononuclear cells isolated from inflamed 
rectosigmoid mucosa in IBD was usually In the range 
detected by the assay. There was significantly more IL-1ß 
produced by mononuclear cells isolated from active 
ulcerative colitis and Crohn’s disease mucosa compared to 
normal mucosa and inactive UC (P<0.01)(Figure 8.11). 
Out of the 15 patients with active UC, 9 who were receiving 
steroid enemas had lower IL-8 levels recorded median 
(range; pg/ml) 190 (20-420), than those six who didn‘t, 220 
(40-440). 
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Table 8.4 P-values comparing IL-10 levels in inflammatory 
bowel disease with healthy controls (P<0.05*). 
Significantly higher values of IL-1ß were recorded from 
ileal biopsies in patients with Crohn's colitis than from 
any other group (Figure 8.12). 
Analysis of variance did not reveal any significant 
difference from the use of systemic steroids and IL-10 
production from isolated mucosal mononuclear cells (F=0.54 
P>0. 10) . 
Stimulation of isolated rectosigmoid mononuclear cells by 
1.0 of E. Coli LPS (Sigma) revealed increased 
production of IL-10 from [median, range, pg/ml]:- 220 (20- 
450) to 240 (30-500) in inflamed UC colon; and increased 
production in healthy colon from 20 (0-60) to 40 (20-120). 
This difference was statistically significant In the two 
groups (P<0.05). 
The intra-assay and inter-assay coefficients of variation 
for the IL-10 ELISA assay were 11.5% and 12.4% 
respectively. 
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8.63 Discussion 
This study shows that mononuclear cells isolated from 
colonic mucosa of patients with active IBD cultured in 
vitro produced much greater amounts of IL-1ß than 
mononuclears isolated from normal colonic mucosa. 
This increase appears to be on a per cell basis as there 
was no significant difference in the proportion of 
macrophages present in the mononuclear cell population from 
normal or inflamed colonic mucosa. 
Enhanced production of IL-1ß by cells isolated from 
inflamed colons is likely to be caused by the presence of 
activated macrophages [Besedovsky et al, 1986]. 
Stimulation with LPS enhanced production of this cytokine, 
by mononuclear cells isolated from inflamed and normal 
colonic mucosa - this is in contrast to the findings by 
Mahida et al who found that LPS resulted in enhanced 
production of IL-1ß only in inflamed mucosa only [Mahida et 
al, 1989]. These particular findings have not been borne 
out by other investigators or by myself, in any case there 
does not appear to me, to be any significance from LPS 
stimulation because LPS has been shown to induce cytokine 
production in all mononuclear cells irrespective of tissue 
type. However, the study by Mahida et al, seems to suggest 
that inflammation is caused by an elite population of 
monocytes. The same reasoning can be applied to IL-8, TNFa 
and IL-1ß production by LPS. 
Macrophages are the major producers of IL-1ß although other 
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cells have also been shown to produce it [Dinarello, 1988]. 
Mahida et al have shown that IL-10 production is markedly 
reduced by depleting the macrophages, by panning with a 
monoclonal antibody [Mahida et al, 1989]. 
Activation of mononuclear cells has previously been shown 
in IBD [Mee et al, 1980; Doe et al, 1982], in addition, 
increased monocyte turnover has been demonstrated [Meuret 
et al, 1978]. It seems likely that during an inflammatory 
response, further monocytes are recruited into the mucosa 
by the action of IL-10, which may then produce further 
release of IL-10 and the generation of oxygen radicals, 
thus triggering the development of an even greater 
inflammatory response. 
The majority of the IBD patients studied were receiving 
corticosteroid treatment. Corticosteroids have been shown 
to inhibit production of pro-inflammatory cytokines in 
vitro [Kern et al, 1988]. In the current study, biopsies 
taken from inflamed sites had greater cytokine production 
compared to non-inflamed sites, I believe these results 
although, also, of an in vitro study more accurately show 
what is happening in vivo. 
In addition to being an important mediator of inflammatory 
and immunological reactions [Dinarello, 1988; Maury, 1986] 
in IBD, IL-1ß is likely to be involved in the repair of 
damaged connective tissue by synthesizing and remodelling 
components of the matrix like collagen, fibronectin and 
proteoglycans [Schmidt et al, 1982; Postlethwaite et al, 
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1983] and may contribute to fibrosis. It may also be 
involved in the induction of mucus secretion. Endothelial 
cells and fibroblasts also produce IL-8 in response to IL- 
1ß and TNFa [Striter et al, 1988; Striter et al, 1989; 
Schroeder et al, 1989], this process indirectly leads to 
neutrophil activation, diapedesis and degranulation. 
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8.7 Interleukin-6 
8.71 Introduction 
Increased serum concentrations of acute phase proteins such 
as a1-acid glycoprotein, al anti-trypsin, CRP, al 
antichymotrypsin, ß2 microglobulin, serum amyloid A have 
been reported to be useful markers for the assessment of 
disease activity in chronic IBD [Weeke et al, 1971; Marner 
et al, 1975; Descos et al, 1979]. These acute phase 
proteins are non-specific markers of inflammation and are 
synthesized mainly in the liver [Koj, 1985]. 
Several cytokines such as IL-6 [Gauldie et al, 1987; Andus 
et al, 19871; IL-1 [Ramadori et al, 1985], TNF [Darlington 
et al, 1986], IFN [Zuraw et al, 1990], TGFß [Mackiewicz et 
al, 1990] have been shown to stimulate acute phase protein 
synthesis in hepatocytes of various species. However, in 
the human, IL-6 has been found to be the most important 
inducer of acute phase protein synthesis (Figure 8.13 - IL- 
6 and acute phase protein production) whereas, IL-1ß and 
TNFa play only minor roles [Castell et al, 1988, Castell et 
al, 1989]. 
IL-6 is synthesized by several cell types including 
macrophages, T-cells, monocytes, endothelial cells and 
fibroblasts. These cells can all be activated independantly 
by various different stimuli such as LPS, TNFa, IFN, and 
viruses. 
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Increased serum IL-6 has been detected during various acute 
phase conditions such as major surgery [Nichimoto et al, 
1989], renal graft rejection [Van Oers et al, 1988] and 
acute pancreatitis [Leser et al, 1991]. In acute 
pancreatitis IL-6 has been reported to be a more sensitive 
marker of disease severity than CRP [Leser et al, 1991]. 
It has been reported that in Crohn's disease there is 
increased levels of serum IL-6 detectable through continuos 
stimulation of IL-6 producing cells but this was not found 
in active UC sera [Gross et al, 1992]. However there have 
been few studies looking at plasma levels simultaneously 
with mucosal levels in the literature. 
Aims, patients and methods 
As described earlier. 
8.72 Results 
The distribution of IL-6 in the plasma, rectosigmoid colon 
and ileum is shown in Figures 8.14, 8.15 and 8.16 
respectively. 
Significantly higher values of IL-6 were recorded from 
rectosigmoid biopsies in patients with active UC and 
Crohn's colitis from those with inactive UC and healthy 
controls (P < 0.001) {Figure 8.15). Out of the 15 patients 
with active UC, 9 who were receiving steroid enemas had 
significantly lower IL-6 levels recorded median (range; 
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pg/ml) 95 (10-230), than those six who didn't 140 ( 5 0 - 3 0 0 ) .  
Table 8.5 P-values comparing IL-6 levels in inflammatory 
bowel disease with healthy controls (p<0.05*). 
As can be seen from Table 8.6 there is virtually no 
difference in plasma IL-6 values from healthy controls to 
patients with IBD. Crohn's ileum again secreted 
significantly more IL-6 than any of the other groups 
studied (Figure 8.15) however patients with active UC had 
levels of spontaneous IL-6 production similar to healthy 
controls. 
Analysis of variance did not reveal any significant 
difference from the use of systemic steroids and IL-1ß 
production from isolated mucosal mononuclear cells (F=0.33 
P>0. 10) . 
Stimulation of isolated rectosigmoid mononuclear cells by 
1.0 of E Coli LPS (Sigma) revealed increased 
production of IL-6 from [median, range, pg/ml]:- 120 (20- 
290) to 150 (20-300) in inflamed UC colon; and increased 
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production in healthy colon from 0(0-20) to 2 0 ( 0- 1 0 0 ) .  This 
difference was statistically significant in the two groups 
(P<0.05). 
There was significant correlation between the levels of 
plasma IL-6 and CRP in Crohn's (r=0.36, P<0.05), and 
between IL-6 and a-1 glycoprotein in active UC (r=0.43, 
P<0.05) . 
The intra-assay and inter-assay coefficients of variation 
for the IL-6 ELISA assay were 6.5% and 9.3% respectively. 
Preliminary studies showed that the amount of IL-6 produced 
by mononuclear cells isolated from inflamed rectosigmoid 
mucosa in IBD was usually in the range detected by the 
assay. 
8.73 Discussion 
This study shows that mononuclear cells isolated from 
colonic mucosa of patients with active IBD, cultured in 
v i t r o ,  produced much greater amounts of IL-6 than 
mononuclear cells isolated from normal colonic mucosa. 
Increased serum levels of IL-6 have been described after 
major surgery and in patients with severe burns or acute 
inflammatory diseases such as bacterial infections or acute 
pancreatitis [Nishimoto et al, 1989; Shenkin et al, 1989; 
Waage et al, 1989]. 
However, in this study increased levels of IL-6 were noted 
in the plasma of patients with Crohn's disease, but not in 
the normal controls or patients with UC. 
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No significant correlation could be found between systemic 
steroid therapy and levels of IL-6, indeed a certain 
proportion of patients treated with steroids had higher IL- 
6 levels than patients with active disease who were not. 
Steroids have been shown to suppress IL-6 synthesis by 
mononuclear cells in vitro [Woloski et al, 1985]. 
Again, I think that once activation of mononuclear cells 
has occured in vivo, systemic steroids do not exert a 
strong influence. 
IL-6 has a relatively short half life in the circulation of 
about 5 minutes [Castell et al, 1988]. It is rapidly 
cleared from the circulation by the liver. Thus a moderate 
increase in the de novo synthesis of IL-6 may lead to 
alterations in the plasma concentration of this cytokine 
for only a short time. Furthermore, IL-6 produced in the 
inflamed bowel may be cleared rapidly by the liver, where 
it induces acute phase protein synthesis before it enters 
the systemic circulation. Presumably, higher IL-6 
concentrations could be found in the portal blood. On the 
other hand, the circulatory lifetime of serum proteins is 
in the range of several days [Putnam, 1975]. Serum 
concentrations of these proteins are therefore, less 
variable than that of IL-6, and remain elevated for a 
longer period. 
The stimulus leading to an increased production of IL-6 in 
IBD can only be guessed, at present, as no hard core 
evidence exists on the aetiology of IBD. 
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Stimuli such as bacterial lipopolysaccharide, viruses, and 
several cytokines such as IL-1ß, TNFa, interferon-?, 
granulocyte colony stimulating factor (GCSF), substance P, 
and substance K stimulate IL-6 synthesis by inflammatory 
cells [Heinrich et al, 1990]. High circulatory endotoxin 
concentrations have been found in patients during the acute 
phase of Crohn’s disease [Fink et al, 1988]. Therefore, one 
must consider that the increase in IL-6 seen in the serum 
might reflect increased endotoxin entering the circulation 
from increased intestinal permeability [Hollander et al, 
1986]. Considering the relatively short half life of IL-6, 
it seems fair to assume that there is continuos 
stimulation, which corresponds to a continuous entry of 
endotoxins into the circulation and/or mucosa. On the other 
hand, this continuous stimulation of IL-6 in IBD may be 
propagated by other cytokines. 
The main points are summarised here but further discussion 
is made in the next chapter. 
Plasma levels of pro-inflammatory cytokines did not 
correlate with disease activity. Possible reasons to 
explain this are:- 
i) the short half lives of the cytokines (5-30 mins) 
ii)after release from the gut mucosa, the cytokines are 
taken via the portal vein to the liver where they are 
rapidly broken down and thus, are never detected in the 
systemic circulation. In an earlier study of patients with 
severe intra-abdominal sepsis [Patel et al, 1994b], I found 
that levels of plasma TNF and IL-1 did not correlate with 
the severity of sepsis. 
Table 8.6 Plasma levels of the proinflammatory cytokines in 
the disease study groups (median with ranges). 
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Plasma levels of the pro-inflammatory cytokines in general 
do not reflect disease activity in IBD. 
In colonic mucosa, high cytokine levels correlated with 
disease activity in both active UC and Crohn's. It is known 
that cytokines play a pivotal role in inflammation, 
therefore, it does not seem surprising that increased 
levels were found in inflamed colon. 
Table 8.7 Levels of the proinflammatory cytokines 
with ranges) which were expressed by isolated rectosigmoid 
mononuclear cells. 
(median 
Levels of pro-inflammatory cytokines in general expressed 
by cultured mononuclear cells do reflect disease activity 
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and expression of cytokine from mononuclear cells taken 
from patients with inactive UC tends to be similar to 
healthy controls. 
Crohn's ileum mononuclear cells express significantly more 
pro-inflammatory cytokines even when taken from 
histologically normal ileum. However, mononuclear cells 
taken from active or inactive UC express similar cytokine 
levels to healthy ileum. 
Table 8.8 Levels of the pro-inflammatory cytokines in the 
disease study groups (median with ranges) which are 
expressed by isolated ileal mononuclear cells. 
NB. The results have been rounded off to the nearest 10 to 
provide clarity. 
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9.1 Introduction 
The clinical entity known as pouchitis was first described 
in continent ileostomies for ulcerative colitis [Kock et 
al, 1977], and later in pelvic ileal pouches [Handelsman et 
al, 1983]. Pouchitis remains a well known complication 
following restorative proctocolectomy, which as the 
patients are followed up longer, the prevalence actually 
increases [Lohmuller et al, 1990], and an incidence of 30% 
has been recently reported [Pemberton et al, 1993]. Like 
UC, the aetiology of pouchitis is unknown and there remains 
controversy in the definition, diagnosis and management of 
this condition. 
The 'cytokine explosion' [Durum et al, 1990] has resurged 
an interest in the intricacies of the inflammatory response 
in many diseases, in the hope of finding abnormal 
regulatory events responsible, if not for triggering, at 
least for the perpetuation of the local tissue damage. If 
this less than ideal goal could be achieved in UC and 
pouchitis, a more rational and effective approach to their 
management could result [Fiocchi et al, 1993] . Pro- 
inflammatory cytokines are known to play an important role 
in the activation of lamina propria mononuclear cells in UC 
and increased levels of TNFa, IL-1ß, IL-6 and IL-8 have 
been reported [Mahida et al, 1992; Mahida et al, 1989; 
Gross et al, 1992; Raab et al, 1993; Pullman et al, 1992; 
Satsangi et al, 1987]. 
However, some investigators have reported decreased levels 
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[Nielsen et al, 1993; Hyams et al, 1991; Gröttrup et al, 
1993] and there has been few studies looking at the pro- 
inflammatory cytokines in both UC and pouchitis [Gionchetti 
et al, 1993]. The similarities in mucosal morphology 
between pouch ileum and the colon in UC, as well as the 
rarity of pouchitis (O-6%) after reservoir formation in 
non-colitics, has led researchers to postulate that the 
pathogenesis of pouchitis involves reactivation of UC 
[Madden et al, 1990; Scott et al, 1989; Penna et al, 1993]. 
The aims of this particular study were to assess whether 
there was increased pro-inflammatory cytokine production by 
the lamina propria mononuclear cells in pouchitis and if 
so, are the levels of these cytokines comparable to UC? 
9.2 Patients and methods 
9.2 1 Mucosal Biopsies 
Mucosal biopsies were obtained from the following:- 
i)25 patients with non-inflamed ileo-anal pouch (median age 
41 years; range 18-57 years) including 5 patients who had 
had an ileoanal pouch after colectomy for polyposis coli. 
ii)9 patients who had a clinical pouchitis (median age 39 
years; range 26-62 years) and 
iii) 20 patients with active UC (rectosigmoid region, median 
age 44 years; range 18-61 years). 
Simultaneous plasma samples were also taken from all 
patients. 
208 
9.22 Control Groups 
Mucosal biopsies were also taken from the following:- 
iv)15 patients with normal ileum (median age 48; range 23- 
64 years), 
v)10 patients with non-specific proctitis (inflammation 
confined to less than 10cm in the rectum) (median age 37; 
range 27-53 years) and 
vi)15 patients with normal colon (median age 49; range 28- 
70 years). Normal ileal and colonic biopsies were taken 
from patients undergoing colectomy for non-IBD disorders. 
9.23 Definition of Pouchitis, active UC and proctitis 
Pouchitis, in this study was described as a combination of 
clinical symptoms of frequency of stools, urgency, passage 
of blood and mucus, sigmoidoscopic findings of inflammation 
associated with friability of mucosa and histological 
criteria of inflammation associated with neutrophil 
infiltration [Kmiot et al, 1993]. 
Patients in the active UC group were classified as having 
moderate-severe UC [Kodner et al, 1990]. 
Patients with non-specific proctitis were defined as those 
where inflammation was confined to less than 10cm in the 
rectum and IBD had been excluded. 
The biopsies were taken either in the operating theatre 
immediately after colectomy together with an ileal biopsy 
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if this was available, or at the time of pouch endoscopy. 
9.24 Mononuclear cell isolation 
Lamina propria mononuclear cells were isolated from the 
mucosal biopsies [Bull et al, 1977]. Briefly, the biopsies 
were placed immediately in cool Hanks buffered saline 
supplemented with glutamine, penicillin, streptomycin (GPS) 
and 10% foetal calf serum (FCS). After mincing, washing was 
carried out. Each of the following steps was preceded by 
washing which consisted of spinning the cells in a 
centrifuge at 1600 RPM for 5 minutes and the supernatant 
would be discarded. 0.75 mM EDTA in Hanks/GPS/FCS was used 
to lyse the epithelial cells and 1 mM dithiothrietol in 
Hanks/GPS/FCS was used to remove surface mucous. Following 
this the tissue matrix was subjected to enzymatic 
dispersion at 37°C with collagenase (Sigma) at conc O. 5mg/ml 
and hyaluronidase (Sigma) at conc 1 mg/ml in RPMI/GPS/FCS 
for 4 hours with pipetting every 20-30 minutes. After 
filtering, the cells were resuspended. Mononuclear cells 
were further separated by Percoll, followed by counting in 
an improved Neubauer chamber. Identity of the mononuclear 
cells was assessed by flow cytometry and viability using 
Trypan blue 1:1, if >95%, further experimentation was 
performed. The cells were suspended in RPMI/GPS/FCS and 
incubated for 48 hours at a concentration of 2 x at 
37°C in a 5% CO, chamber. The supernatants were stored at - 
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80 °C. The cells were quantitated at the end of the culture 
period and cytokine release corrected for the number of 
cells alive and viable. 
9.25 Cytokine Elisa 
Plasma cytokine levels were determined, (as previously 
described in chapter 8 & Helle et al, 1990), using 
monoclonal antibody for TNFa (British Biotechnology), IL-1ß 
(Janssen, Belgium) and IL-6 (Monosan, Belgium) and IL-8 
(British Biotechnology). Plasma levels of C-reactive 
protein (CRP) and a1 acid glycoprotein were also measured 
by immunoturbidometric assay. 
9.26 Statistical analysis 
Results were not normally distributed and have therefore, 
been expressed as medians with ranges. The Mann-Whitney U 
test has been employed to show differences between the 
cytokine levels in the subgroups. The Spearman rank 
correlation has been used to show associations. 
9.3 Results 
The distribution of the findings for the individual 
cytokines TNFa, IL-1ß, IL-6 and IL-8 are shown in Figures 
9.1-9.4 respectively. Pro-inflammatory cytokine production 
was significantly increased (P < 0.05) in the inflamed 
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ileoanal pouch (pouchitis) compared to healthy control 
ileal biopsies (Table 9.1). 
Patients with a non-inflamed pouch who were relatively 
symptom free also had significantly raised IL-6 and IL-8 
levels compared to healthy controls which was statistically 
significant (P<0.05) . 
Subgroup analysis of the non-inflamed ileo-anal pouch 
patients (n=20) revealed that with a long standing pouch 
(>2years; n=9) significantly greater levels of mucosal IL-6 
and IL-8 [190 (0-370) and 150 (40-420) pg/ml respectively] 
were found compared to recently constructed ileo-anal 
pouches (<2 years ; n=11) [130 (0-260) and 110 (30-300) 
pg/ml, respectively. However no significant differences 
were noted for IL-1ß and TNFa! in this subgroup analysis. 
There was significant correlation between the CRP and IL- 
1ß, IL-6, IL-8 (Table 9.2) and between al-glycoprotein and 
IL-6. 
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As previously shown in chapter 8 plasma levels of cytokines 
again did not differ significantly from controls. 
Table 9.2. Correlation matrix showing comparison between C- 
reactive protein, al-glycoprotein and pro-inflammatory 
For patients with proctitis, higher levels of the pro- 
inflammatory cytokines were noted, compared to normal colon 
controls. A greater level of cytokine expression was noted 
in active UC compared to proctitis, even though the grade 
of inflammation for some patients, in the two groups, was 
comparable histologically. 
Stimulation of isolated mononuclear cells from inflamed 
(active UC) and non-inflamed mucosa with 1.0 E.  Coli 
LPS (sigma) revealed increased cytokine expression in both 
groups, as described in Chapter 8. 
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9.4 Discussion 
Levels of the pro-inflammatory cytokines have been shown to 
be elevated in a variety of chronic inflammatory 
'autoimmune' diseases such as rheumatoid arthritis, 
Wegener's granulomatosis, systemic lupus erythematosis, 
polyarteritis nodosa and also recently in ulcerative 
colitis and Crohn's disease [Mahida et al, 1992; Mahida et 
al, 1989; Raab et al, 1993; Patel et al, 1993; Brynskov et 
al, 1992]. 
This study has shown that mucosal levels of the pro- 
inflammatory cytokines IL-1ß, IL-6, IL-8 and TNFa are not 
only elevated compared to healthy controls, but are also 
comparable in active chronic UC and pouchitis. One can 
argue that this, in vitro finding may not reflect the in 
vivo mucosal environment, and also that these findings 
simply reflect the local inflamation seen in both 
conditions. However, on the other hand could pouchitis 
represent a reactivation of the immunological mechanisms 
which led to active UC. In favour of this hypothesis, is 
the finding that some patients with pouchitis, have 
resurgence of the extra-intestinal manifestations of UC in 
the same way as patients who have active UC [Lohmuller et 
al, 1990 ]. RFD9 macrophages have been found to be present 
in the mucosa of patients with active UC, but do not appear 
as a non-specific response in infectious colitis. However, 
they are also present in pouchitis, which suggests that 
similar effector mechanisms for triggering the original UC 
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may be operating in pouchitis [Gionchetti et al, 1993]. 
In this study, mononuclear cytokine production is compared 
in ileum and colon, on the premise that pouchitis may 
represent a reactivation of ulcerative colitis in mucosa 
which has undergone colonic metaplasia and villous atrophy. 
The levels of cytokines expressed in some patients with 
active IBD were much greater quantitatively than those 
expressed in non-specific proctitis which histologically 
had the same degree of inflammation noted. When pouchitis 
is diagnosed endoscopically, histological evidence of acute 
inflammation is invariably present, ie. neutrophil 
infiltration, crypt abscesses, and ulceration [Tytgat et 
al, 1988]. These findings are very similar to the features 
seen in active UC and is far more common for UC than for 
familial adenomatous polyposis [Nicholls et al, 1985;  
Shepherd et al, 1987]. 
A typical feature of the acute inflammatory response in 
active UC and in pouchitis is mucosal ulceration and 
neutrophil infiltration [Goldman, 1984; Moskowitz et al, 
1986]. 
If the neutrophil is considered to be the main inflammatory 
cell, then by what mechanisms is it activated? The 
mechanisms responsible for the recruitment and activation 
of neutrophils in the mucosa In UC and pouchitis are 
probably multifactorial and the mediators of the 
inflammatory changes are cytokines. 
IL- 8  is a powerful neutrophil chemoattractant [Baggiolini 
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et al, 1989]. Our findings with those of others [Mahida et 
al, 1992; Raab et al, 1993; Izzo et al, 1992] of increased 
mucosal IL-8 in UC and in pouchitis make it very likely 
that this cytokine is an important mediator in the 
activation, diapedesis through vascular endothelium and 
focal recruitment of neutrophils at the site of 
inflammation [Striter et al, 1988]. What factors are 
responsible then for inducing increased IL-8 production? 
Immune complexes, endotoxins and several cytokines 
including IL-1ß and TNFa have been shown to be potent 
inducers of IL-8 [Baggiolini et al, 1989; Striter et 
al,1988; Striter et al, 1989; Colditz et al, 1989]. 
This study together with another recent study which found 
an increased TNFa concentration in colonic-rectal perfusate 
fluid in UC which significantly correlated with increased 
IL-8 release suggests that TNF is one possible mediator in 
the increased IL-8 synthesis in active UC [Raab et al, 
1993]. 
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The following flow chart is a hypothesis of the sequence of 
events which may occur:- 
Chronic UC-Total Colectomy 
Normal ileum 
Ileo-anal pouch operation (normal ileum) 
Pathological changes in the ileum resulting from a change in the 
physiological role of the ileum :- 
1. stasis 
2.perturbation of the bacterial flora in the ileum (3.nutritional 
deficiences) 
(4.ischaemia) 
Changes in the morphological structure of the ileum as a result of 
one or a combination of these factors leading to villous atrophy and 
colonic metaplasia 
Histological change in the ileum to colon and leading to 
immunological recognition of the ileum as colon and subsequent 
reactivation of the mechanisms which led to ulcerative colitis 
Pouchit is 
Successful treatment with metronidazole 
Decrease of gram-ve bacteria and anaerobic bacteria from the ileum or 
an immunosuppressive as yet undefined action of metronidazole leading 
to reversal of the ileal changes and disease remission. 
In Figure 9.5 is shown a proposal of cytokine mechanisms 
operating in active ulcerative colitis and pouchitis. 
Endothelial cells and fibroblasts have also been shown to 
produce increased amounts of both IL-6 and IL-8 in response 
to IL-1 and TNF [Striter et al,1988; Striter et al, 1989; 
Schroeder et al, 1989]. This could explain the increased 
IL-6 levels noted in this study and those of others [Gross 
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et al, 1992]. IL-6 is the most potent inducer of acute 
phase protein synthesis by the liver whereas IL-1ß and TNFa 
have been shown to play a relatively minor role [Castell et 
al, 1989; Castell et al, 1988] therefore it doesn't seem 
surprising that in this study IL-6 correlated significantly 
with CRP in both pouchitis and UC. 
Investigation into the role of cytokines in general which 
lead to inflammation in UC are at an early stage. Perhaps 
by studying patients with pouchitis we can unravel some of 
the intricacies of the inflammatory response which occurs 
in UC in the hope of finding new therapeutic modalities 
[Youngman et al, 1993]. 
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9.5 Summary 
Controversy exists as to whether pouchitis represents a 
reactivation of the immunological mechanisms which led to 
ulcerative colitis (UC). The aims of this study were to 
determine local levels of the cytokines:- interleukin-1ß 
(IL-1ß), interleukin-6 (IL-6), interleukin-8 (IL-8) and 
tumour necrosis factor alpha (TNFa) in the mucosa of 
patients with normal ileum (n=15), ileoanal pouch for UC 
(n=20), pouchitis (n=9) and active ulcerative colitis ( 
n=20). Lamina propria mononuclear cells were isolated from 
mucosal biopsies, by enzymatic dispersion, and cultured for 
48 hours. Pro-inflammatory cytokine levels were measured in 
the supernatants. IL-10, IL-6, IL-8 and TNFa secretion was 
significantly greater in pouchitis and active UC then in 
the non-inflamed ileoanal pouch and normal ileum (P<0.001). 
There was significant correlation (r=0.63, P<0.05) between 
levels of cytokines expressed in pouchitis and active UC. 
Perhaps pouchitis represents a reactivation of UC in mucosa 
which has undergone colonic metaplasia and villous atrophy. 
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10.1 Summary 
These studies were designed to assess the role of 
autoantibodies, soluble adhesion molecules and pro- 
inflammatory cytokines in patients with ulcerative colitis 
and following restorative proctocolectomy. 
The findings are summarized below:- 
CHAPTER 2:- ANCA were originally described in patients with 
systemic vasculitis and they are found in the majority of 
patients with ulcerative colitis. ANCA persist in high 
titre in the sera following total colectomy for severe UC. 
The prevalence of ANCA in pouchitis was 100%. 
CHAPTER 3:- Sera from patients with ulcerative colitis 
recognise a variety of antigens on the neutrophil namely 
lactoferrin, cathepsin G, enolase and elastase. These 
antigens are not the commonly encountered antigens of ANCA 
in sytemic vasculitides, which are proteinase 3 and 
myeloperoxidase. 
CHAPTER 4 :-  Confocal laser microscopy localised the ANCA 
antigens to the intra-nuclear portion of the neutrophil, 
and not the peri-nuclear or cytoplasmic portion. This has 
been attributed to the method of fixation of the 
neutrophils using ethanol. There are no other studies to 
date relating to these findings. 
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CHAPTER 5 :-  AECA is also found in sera from patients with 
ulcerative colitis and Crohn's disease, thus providing 
further serological proof of vasculitis in UC as well as 
Crohn's disease. 
CHAPTER 6 :-  Other autoantibodies including AECA, anti-EPI 
and anti-tropomyosin also persist, despite total colectomy, 
suggesting that immunological mechanisms are not halted by 
removal of the target organ (the colon) in UC. The cross- 
reactivity of ANCA with anti-EPI antibodies using 
adsorption studies may help to explain the high prevalence 
of ANCA in UC. 
CHAPTER 7:- Soluble adhesion molecules ICAM-1, E-Selectin 
but not VCAM-1, may be used as markers of disease activity 
in UC. 
CHAPTER 8 : -  Pro-inflammatory cytokines, namely IL-1ß, IL-6, 
IL-8 and TNFa, produced by lamina propria mononuclear 
cells, are increased in active UC and Crohn's disease, when 
compared to healthy controls and inactive ulcerative 
colitis. The levels of cytokines in the plasma do not 
increase in UC, but slight increases in Crohn's disease 
have been noted, suggesting that there might be a greater 
expression of these cytokines locally, which pass through 
the liver and spill over into the plasma. 
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CHAPTER 9:- There is similar quantitative expression of 
pro-inflammatory cytokines in both active UC and pouchitis 
but not in non-specific proctitis. These findings seem to 
suggest that perhaps, pouchitis is not merely a 
complication of ileoanal pouch surgery, but reactivation 
of UC in ileal mucosa which has undergone villous atrophy 
and colonic metaplasia. 
10.2 Hypothesis A 
'Ulcerative colitis is a 'gut limited' vasculitis which 
bears immunological resemblances to systemic vasculitis'. 
The following have been found to occur in both groups of 
diseases: 
1. ANCA 
2. AECA 
3.Autoantibodies persist following target organ removal 
such as the colon, which suggests that immunological 
mechanisms are not halted by colectomy in UC. 
Why should these autoantibodies persist? 
eg. Taking tetanus as an example, immunity wanes with time 
and we need to have a booster. So were the samples to 
measure titres taken too early, does one need to wait for 
10 years to see if the titres will fall? 
Secondly, if the immune system is to blame for this 
disorder are we to assume that the colon is entirely normal 
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in UC? 
If the latter is true, than by manipulation of the immune 
system, one may be able to control the disease in the 
future without the need arising for colectomy. 
The neutrophil has a central role in bringing about the 
inflammation in UC. Increased soluble adhesion molecules in 
the sera may not only be used as markers of disease 
activity but also, inhibitors of these molecules could be 
employed to dampen the transmigration of neutrophils and 
subsequent inflammation. 
10.3 Hypothesis B 
Pouchitis bears immunological resemblances to UC, and 
represents reactivation of UC. 
ANCA have been found in a large majority of patients with 
active UC and all patients with pouchitis, but are not 
found in infective colitis. 
Pro-inflammatory cytokine production, quantitatively is 
similar in both active UC and pouchitis but not in non- 
specific proctitis, even though histological similarities 
have been reported. 
10.4 Further Research and future prospects. 
The in vivo role of autoantibodies in systemic vasculitis 
is thought to be a cytotoxic role. However, so far there is 
no convincing evidence for such a role in UC and further 
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study is needed to assess any cytotoxicity both in vitro 
and in vivo. 
In vitro, cytotoxicity could be assessed using Chromium 51 
assays after isolating the antibodies by HPLC. 
Finally, the mechanisms by which the pro-inflammatory 
cytokines exert their action in vivo are poorly understood. 
One of the main reasons for this is that there are so many 
of them - up to 140 have been described and the number is 
growing every day. They have a pleiotropic mode of action 
and this makes their pathophysiological complexity immense. 
10.5 New Treatments 
Increasing knowledge of intestinal inflammatory processes 
in the inflammatory bowel diseases has been obtained in the 
last 5 years, based on clinical, immunologic and 
biochemical studies. The inflammatory response in the the 
colonic mucosa may evolve in 3 stages:- 
1. Activation of the immune system 
2.Production of inflammatory mediators with subsequent 
amplication of this response 
3.Destructive interactions of activated inflammatory cells 
with gut epithelium. 
Pharmacologic intervention at each of these stages is 
regarded a desirable therapeutic goal in the absence of a 
known aetiology. 
Phospholipase-A2, lipoxygenase inhibitors, radical 
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scavengers, mediator (cytokine) receptor antagonists or 
modification of mediators with less active derivatives are 
examples of recent developements [Allgayer et al, 1990]. 
Vasculitis has been well described in rheumatoid arthritis 
but not in UC. It is interesting to note that patients with 
rheumatoid arthritis are now being treated with a drug 
which is commonly used in IBD, namely salazopyrine 
[Hilliquin et al, 1992; Murphy, 1992]. 
Pooled immunoglobulin have been shown to be of benefit in 
patients with systemic vasculitis who have relapsed on 
conventional steroid and cyclophosphamide therapy [Jayne et 
al, 1991]. Recently, some benefit has been reported in the 
treatment of IBD [Levine et al, 1992). Currently, pooled 
immunoglobulins are undergoing evaluation in the 
Departments of Renal medicine and Rheumatology at the Queen 
Elizabeth Hospital, Birmingham for the treatment of 
systemic vasculitis. 
It seems interesting also to note that there appears to be 
nothing documented in the literature, on the use of 
cyclophosphamide in IBD, which is the standard first line 
treatment in systemic vasculitis. 
Systemic vasculitis and UCrarely occur together. Anecdotally, I came across 
such a young man, who had polyarteritis nodosa and went on to develop 
UC. His major symptoms were chronic non-healing leg ulcers, despite 
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multiple skin grafts, since 1 O years and colitis since 2 years . His symptoms 
of colitis had shown improvement on only steroids and cyclophosphamide 
therapy. Following withdrawal of cyclophosphamide treatment because of 
a herpetic penile ulcer, his UC became uncontrollable on medical 
management, and he underwent total colectomy for severe UC. Skin grafts 
on his leg ulcers which had initially taken well a few months previously,, 
also broke down simultaneously at this time. An ileoanal pouch procedure 
was then carried out. 
Eighteen months following the procedure, he developed pouchitis several 
times, which has been successfully treated with metronidazole. Of interest, 
is the fact that during episodes of pouchitis, his leg ulcers increased in size 
and severity. Serological investigation during an acute episode of pouchitis 
revealed presence of ANCA, AECA and anti-EPl autoantibodies. The ulcers 
on the legs became quiescent again, once his symptoms of pouchitis 
improved. This case serves to illustrate several of the points discussed in 
this thesis. 
Cyclophosphamide is a standard immunosuppressant usually 
used in systemic vasculitis and malignancy. It may be of 
benefit in certain cases of UC. However, its use in this 
disease needs to be evaluated further, bearing in mind all 
its side effects. 
Other immunosuppressants/cytotoxics such as 6- 
mercaptopurine have shown some benefit in inducing 
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remission in UC [Adler et el, 1990]. Potential benefits 
have also been documented from cyclosporin and azathioprine 
use, but their use has not yet been universal. 
IL-1ß receptor antagonist has been found to have some 
benefit in experimental colitis [Cominelli et al, 1992] and 
clinical trials are currently underway to assess its role 
in ulcerative colitis. 
This thesis has looked at and developed immunological 
methods which are relatively new, in the study of patients 
with ulcerative colitis, and used two immunological models 
for comparison namely pouchitis and systemic vasculitis. 
The results, thus far, look encouraging and there is hope 
for future studies looking at the mechanisms of 
inflammation, in order to develop new treatments for this 
disease. 
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APPENDIX 1 
REAGENTS 
Dulbecco,s B phosphate buffered saline 
NaCl 
KCl 
PBS-Tween 20 
NaCl 
KCl 
.12 
Tween 20 
8.0 137. O 
0.2 2.7 
1.15 8. 
0.2 1.5 
0.1 0.9 
0.1 0.5 
8.0g 
2.8g 
O. 5ml 
0.2g 
0.2g 
Make up to 1 litre with distilled water 
Substrate Buffer for alkaline phosphatase 
Diethanolamine 
Distilled water 
97ml 
100mg 
200mg 
900ml 
Add concentrated KCl (10M) until pH of solution is 9.8 
White Cell Staining Fluid 
20% acetic acid + Gentian violet ( 2 drops per ml) 
Methyl Green 
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Methyl green (Sigma) 0.025g 
Glycerol lml 
Distilled water 9ml 
The dye is added just before end of the electrophoresis 
using a spinal needle. Great care is taken not to 
contaminate the dye solution with running buffer after 
application as the alkaline nature of the buffer tends to 
turn the dye colourless. 
Coomassie Blue Stain 
2.5g Brilliant Blue R (Sigma) 
Dissolve in 250ml ethanol, then add 250 ml distilled 
water 
and 50ml glacial acetic acid. Stir for 30 minutes then 
filter with Whatman No 1 paper. Stain for 3 hours. 
Gel Destaining Solution 
70% distilled water 
20% ethanol 
10% glacial acetic acid 
Destain for 2-3 days. 
Substrate AEC preparation for immunostaining 
Dissolve 1 AEC tablet (3amino 9ethyl carbazole, Sigma) in 
2.5ml of dimethyl foramide (DMF, Sigma). Add 2.5 ml of 
AEC-DMF to 47.5 ml of 50mM acetate buffer pH 5.0 with 
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stirring. Add 25 of fresh 30% hydrogen peroxide 
immediately prior to use. Filter the solution through a 
0.2 filter. 
Acetate buffer :- add 74 ml of 0.2M acetic acid (11.55ml 
of glacial acetic acid) and 176 ml of 0.2M sodium acetate 
buffer (27.2 g sodium acetate trihydrate/l) to 1 litre of 
deionized water and mix. 
Reagents for SDS-PAGE 
Stock Reagent Preparation 
A. Acrylamide/Bis (30% T, 2.67% C) 
Acrylamidel46.0g 
N'N - bis-methylylene-acrylamide 4.0g 
Distilled water to 500ml. Filtered and stored at 4°C in 
the 
dark. Maximum shelf life under these conditions is 30 
days. 
B. 1.5M Tris-HCl, pH 8.8 
54.45 g Tris base 
150 ml distilled water 
Adjust to pH 8.8 with 10 N HC1. Distilled water to 300ml. 
Store at 4°C. 
C. 0.5M Tris-HC1, pH 6.8 
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6g Tris base 
60ml distilled water 
Adjust to pH 6.8 with 10N HC1. Distilled water to 100ml. 
Store at 4°C. 
D. 10% (w/v) SDS 
Dissolve 10g SDS in water with gentle stirring. Distilled 
water to 100ml. 
E. 1 O % Ammonium persulphate (w/v) 
100 mg ammonium persulphate. 
Distilled water to 1 ml. Make fresh daily. 
F.Sample buffer (SDS reducing buffer: 62.5 mM Tris-HC1, pH 
6.8, 10% glycerol, 2% SDS, 5% Mercaptoethanol) 
Distilled water 3.8ml 
0.5M Tris-HC1, pH 6.8 1. 0ml 
Glycerol O. 8ml 
10% SDS 1.6ml 
ß-mercaptoethanol O. 4ml 
0.05%(w/v)Bromophenol blue (in water) 0.4ml 
Total 8. 0ml 
Dilute the sample at least 1:4 with sample buffer. Heat 
at 95-99°C for 4 minutes. 
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G.5 x Electrode (Running) Buffer (25 m M  Tris, 192 m M  
glycine, 1% SDS, pH 8.3) 
Tris base 45.0g 
Glycine 216.0g 
SDS 15. 0g 
Distilled water to 3 litres. Store at 4°C. Warm to 37°C 
before use if precipitation occurs. Dilute 300 ml 5 x 
stock with 1.2 L distilled water for one 
electrophoretic 
run. 
H.TEMED - N,N,N’,N’-Tetramethylethylenediamine 
Molecular formula . 
Store at room temperature 
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Appendix 2 
Viability of the cells was assessed with Trypan blue 1:l 
and if >95% further experimentation was performed. The 
cells were incubated in Nunc cell culture plates for 48 
hours with nothing or with 1 of E.Coli 
lipopolysaccharide (Sigma) at a concentration of 2 x 
at in a 5% CO, chamber. 
The maximal secretion of IL-8, TNFa, and IL-6 by 
addition of lipopolysaccharide to the mononuclear cells was 
determined on biopsies obtained from 5 healthy patients. 
Lipopolysaccharide at concentrations of 0.001, 0.01, 0.1, 
1.0, and 10 micrograms/ml was used. 
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Anatomical Site and cytokine production 
Preliminary studies looking at TNFa production by 
mononuclear cells from 4 different anatomical sites in the 
colon were undertaken: 
a.ascending colon 
b.transverse colon 
c.descending colon 
d.rectosigmoid colon 
Study of mononuclear cells in 6 patients did not reveal any 
significant difference in the amount of cytokine produced 
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by anatomical site in healthy colon. 
Coating Buffer 
Add 1.59g to 500 ml distilled water 
Add 2.93g NaHCO, to 500 ml distilled water 
Add together until 9.6 
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